<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uremic toxins</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uremic toxins</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uremic toxins</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raymond Vanholder, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The uremic syndrome can be defined as the deterioration of multiple biochemical and physiological functions in parallel with progressive kidney dysfunction, thereby resulting in complex but variable symptomatology [<a href="#rid1">1-7</a>]. Normally, healthy kidneys excrete a myriad of compounds. Uremic retention solutes accumulate in patients with chronic kidney disease (CKD), including those with end-stage kidney disease (ESKD) [<a href="#rid8">8</a>]. The retention of these solutes is directly or indirectly attributable to deficient kidney clearance.</p><p>These retained solutes are called uremic toxins when they contribute to the uremic syndrome. Apart from inorganic compounds that have an established role, only a few compounds conform to the strictest definition of uremic toxins. However, this does not preclude a potential role for various other retention solutes. (See  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a>.)</p><p>Uremic toxins have traditionally been subdivided into three major groups based upon their chemical and physical characteristics, essentially because of the role of those characteristics in removal by conventional dialysis strategies:</p><p class="bulletIndent1"><span class="glyph">●</span>Small, water-soluble compounds with no or minimal protein binding, such as urea</p><p class="bulletIndent1"><span class="glyph">●</span>Small, lipid-soluble compounds with substantial protein binding, such as the phenols</p><p class="bulletIndent1"><span class="glyph">●</span>Larger, so-called middle molecules, such as beta2-microglobulin (beta2-m)</p><p></p><p>However, more granular classifications have been proposed [<a href="#rid9">9</a>], in part because of the availability of newer dialyzer membranes (eg, medium cut-off [MCO] membranes) that allow for removal of larger compounds than previous membranes. Regardless of classification schemata, uremic retention solutes occupy continuums with regards to protein binding, molecular weight, and presumed toxicity [<a href="#rid10">10,11</a>]. </p><p>Views on the uremic syndrome and several uremic solutes have changed substantially over time [<a href="#rid5">5,12</a>]. The biochemical, physiologic, and/or clinical impact of the most important and the most extensively studied toxins are presented here [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H2"><span class="h1">SMALL WATER-SOLUBLE COMPOUNDS</span></p><p class="headingAnchor" id="H3"><span class="h2">Urea</span><span class="headingEndMark"> — </span>Many studies demonstrate a toxic (biological) effect of urea at chronic kidney disease (CKD)-relevant concentrations [<a href="#rid13">13,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Urea inhibits Na-K-2Cl cotransport in human erythrocytes, as well as a number of cell volume-sensitive cellular transport pathways [<a href="#rid15">15</a>]. The Na-K-2Cl cotransport is a ubiquitous process that serves numerous vital functions, including cell volume and extrarenal potassium regulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urea inhibits macrophage-inducible nitric oxide (NO) synthesis at the posttranscriptional level [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As the most important osmotically active uremic solute, urea may provoke dialysis disequilibrium if the decrease in plasma concentration of urea during dialysis occurs too rapidly. (See  <a class="medical medical_review" href="/z/d/html/1851.html" rel="external">"Dialysis disequilibrium syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With increasing kidney dysfunction, increasing amounts of cyanate are spontaneously transformed from urea. The active form of cyanate, isocyanic acid, carbamylates proteins and other molecules, thereby affecting their structure and function [<a href="#rid17">17</a>]. The resulting increase in carbamylated solutes has been linked to endothelial cell death and smooth muscle cell proliferation [<a href="#rid18">18</a>], monocyte adhesion to endothelium [<a href="#rid19">19</a>], and inhibition of endothelial cell repair [<a href="#rid20">20</a>]. All of these factors play a role in vascular damage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of adipocytes with disease-relevant urea concentrations induced radical oxygen species production, caused insulin resistance, and increased modified insulin signaling molecules in one study [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urea induced in vitro intestinal barrier dysfunction in one study, which could play a role in the increased leakiness of the gut for endotoxin, which has a proinflammatory potential [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In human smooth muscle cells, urea induced apoptosis and cell death, which may contribute atherogenesis and progression of atheromatosis [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase in radical oxygen species generation and activation of several other proinflammatory and proatherogenic pathways was demonstrated in arterial endothelial cells [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulin resistance was induced in pancreatic beta cells [<a href="#rid25">25</a>].</p><p></p><p>It has been hypothesized, however, that the possible toxic effects of urea are counterbalanced by the simultaneous retention of methylamines [<a href="#rid26">26</a>].</p><p>Findings in in vitro and animal studies that suggest a toxic effect of urea have not been corroborated by clinical studies [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The lack of correlation with symptoms of the uremic syndrome after addition of urea to the dialysate [<a href="#rid28">28</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The missing impact in the Hemodialysis (HEMO) and Adequacy of Peritoneal Dialysis in Mexico (ADEMEX) studies of an increase in urea removal on outcome [<a href="#rid29">29,30</a>]</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Guanidines</span><span class="headingEndMark"> — </span>The guanidines are a large group of structural metabolites of arginine. Several of the guanidino compounds modify key biological functions:</p><p class="bulletIndent1"><span class="glyph">●</span>Guanidinosuccinic acid and guanidinopropionic acid inhibit neutrophil superoxide production [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guanidino compounds exert both pro- and antiinflammatory effects upon leukocytes [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guanidinosuccinic acid, gamma-guanidinobutyric acid, methylguanidine, homoarginine, and creatine induce seizures after systemic and/or cerebroventricular administration in animals [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A mixture of guanidino compounds suppresses the natural killer cell response [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guanidines cause structural damage to proteins by deamidation/isomerization, which in turn reduces the binding of homocysteine [<a href="#rid36">36</a>].</p><p></p><p>Although not observed in all studies [<a href="#rid37">37</a>], most investigations have found that NO synthesis is inhibited in patients with end-stage kidney disease (ESKD). This may result in vasoconstriction, hypertension, immune dysfunction, and neurologic abnormalities.</p><p>Although arginine (which is also a guanidino compound) markedly enhances the production of NO, some of the other guanidines, as arginine analogs, are strong, competitive inhibitors of NO synthase. Asymmetric dimethylarginine (ADMA), which is significantly increased in ESKD [<a href="#rid38">38</a>], is the most specific endogenous compound with inhibitory effects on NO synthesis. In the brain, ADMA causes vasoconstriction and inhibition of acetylcholine-induced vasorelaxation [<a href="#rid39">39</a>]. It has also been implicated in the development of hypertension, adverse cardiovascular events [<a href="#rid40">40-43</a>], progression of kidney function impairment [<a href="#rid44">44</a>], kidney fibrosis [<a href="#rid45">45</a>], and mortality (see  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a>). Administration of ADMA to healthy volunteers resulted in an increase of vascular resistance and blood pressure in a dose-related manner [<a href="#rid43">43</a>]. It was also demonstrated that ADMA increased vascular stiffness and decreased cerebral perfusion in healthy subjects [<a href="#rid46">46</a>]. ADMA has also been linked to polymorphonuclear activation [<a href="#rid47">47</a>] and to expression of adhesion molecules [<a href="#rid48">48</a>]. It has been suggested, based on solute dialysance data, that ADMA was protein bound [<a href="#rid49">49</a>].</p><p>The increase in symmetric dimethylarginine (SDMA), the steric variant of ADMA, is more pronounced than that of ADMA. Although this compound had been considered biologically inactive, SDMA was linked to an increase in reactive oxygen production and an inhibition of NO synthesis [<a href="#rid50">50</a>]. SDMA was also associated with an increase in free radical production by leukocytes; this effect was attributed to an increased calcium influx via store-operated Ca<sup>2+</sup> channels (SOCs) [<a href="#rid51">51</a>]. In an extensive study that evaluated a panel of guanidino compounds on several cell systems involved in vascular damage, SDMA most consistently induced proinflammatory effects in various types of leukocytes [<a href="#rid33">33</a>]. In addition, SDMA also induced monocytic cytokine production, in contrast to ADMA [<a href="#rid52">52</a>]. In the clinical arm of this study, SDMA in CKD patients was more significantly correlated to interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha) levels compared with ADMA [<a href="#rid52">52</a>]. SDMA also modified high-density lipoprotein (HDL) into an abnormal molecule, inducing endothelial damage [<a href="#rid53">53</a>].</p><p>The generation of the guanidines synthesized from arginine in the proximal convoluted tubule, such as guanidinoacetic acid and creatine, is depressed in ESKD [<a href="#rid54">54</a>]. The reported concentration of guanidinoacetic acid is not elevated among uremic individuals [<a href="#rid7">7</a>]. On the other hand, the synthesis of guanidinosuccinic acid, guanidine, and methylguanidine is markedly increased, which appears to be due to urea recycling. The reported concentrations of guanidinosuccinic acid and methylguanidine are increased in uremia compared with normal concentrations  (<a class="graphic graphic_table graphicRef85916" href="/z/d/graphic/85916.html" rel="external">table 1</a>) [<a href="#rid7">7</a>].</p><p>Dialytic removal of the guanidines, despite their low molecular weight, is not consistently comparable with that of urea. Many of these compounds display different intradialytic behavior compared with urea, suggesting a pluricompartmental distribution [<a href="#rid55">55,56</a>]. In the absence of protein binding, this behavior points to a retardation in the transfer of these molecules from inside to outside of cells. These findings have been confirmed from direct estimations [<a href="#rid57">57</a>]. Further mathematical analysis revealed that increasing dialysis time was the preferred strategy to improve removal of guanidine compounds that had larger distribution volumes (such as methylguanidine, for example), whereas more frequent dialysis preferably impacted upon compounds with a smaller distribution volume (such as guanidinosuccinic acid) [<a href="#rid58">58</a>]. Optimal results were obtained with a combination of daily and long, slow dialysis [<a href="#rid58">58</a>].</p><p>Nondialytic removal of ADMA is less dependent on renal excretion than on metabolic transformation, which is inhibited in the setting of kidney failure. Enhancing metabolism might decrease ADMA concentration. Proof of principle is suggested by studies that showed that genetic overexpression of the ADMA-degrading enzyme, dimethylarginine dimethylaminohydrolase, was cardioprotective in mice following heart transplantation [<a href="#rid59">59</a>]. Furthermore, since the transmethylation reaction catalyzed by this enzyme is stimulated by lowering homocysteine levels, ADMA concentration was decreased by coadministration of intravenous methylcobalamin and oral folate [<a href="#rid60">60</a>]. These data illustrate how uremic solutes may influence each other's concentration and how removal depends not only on kidney function and dialysis but also on metabolism, which can be influenced externally by administration of drugs, vitamins, or nutritional additives.</p><p class="headingAnchor" id="H8"><span class="h2">Oxalate</span><span class="headingEndMark"> — </span>Massive oxalate retention is uncommon in dialyzed patients, except in primary hyperoxaluria [<a href="#rid61">61</a>]. In this disorder, production is increased due to genetically mediated alterations of oxalate metabolism. (See  <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">"Primary hyperoxaluria"</a>.)</p><p>Among patients with ESKD without primary hyperoxaluria, serum oxalate concentrations are increased approximately 40-fold compared with healthy controls [<a href="#rid62">62</a>]. Secondary oxalosis in such patients is characterized by the deposition of calcium oxalate in multiple tissues, which was mostly observed in early kidney replacement therapy with inefficient dialysis strategies [<a href="#rid63">63</a>]. Oxalate resulted in an increase of intracellular calcium in endothelial cells [<a href="#rid64">64</a>], leading to disturbed endothelial proliferation and repair [<a href="#rid64">64,65</a>]. Oxalate also decreases glucuronidation, a detoxifying conjugation process [<a href="#rid66">66</a>].</p><p>Oxalate accumulation may be worsened by excessive intake of oxalate precursors, including ascorbic acid, green leafy vegetables, rhubarb, tea, chocolate, or beets. In addition, those with inflammatory bowel disease are at risk for this complication.</p><p>The role of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> (vitamin B6) in uremic oxalate accumulation remains a matter of debate. In rats with kidney failure, pyridoxine depletion results in increased urine oxalate excretion and depressed kidney function [<a href="#rid67">67</a>]. In hemodialysis patients, pyridoxine at 800 mg/day causes a decrease in oxalate concentration [<a href="#rid68">68</a>]. However, such high doses of pyridoxine may induce gastrointestinal intolerance.</p><p>Dialytic removal of oxalate is similar to that of urea and, therefore, is relatively easy with any of the classic dialysis strategies. However, since removal is lower than clearance from the body in healthy controls, serum concentrations of oxalate among dialyzed patients remain higher than normal [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H4267309409"><span class="h2">Trimethylamine-N-oxide (TMAO)</span><span class="headingEndMark"> — </span>TMAO has long been recognized as a component of uremic biological fluids [<a href="#rid70">70</a>]. Increased TMAO may be a potentially important risk factor for cardiovascular disease and mortality in the general population [<a href="#rid71">71,72</a>] and in patients with CKD [<a href="#rid73">73,74</a>]. TMAO also may contribute to progression of kidney disease [<a href="#rid74">74,75</a>].</p><p>In spite of a substantial number of studies supporting the toxic role of TMAO [<a href="#rid75">75</a>], the compound is also known as a protein stabilizer [<a href="#rid76">76</a>], while fish, one of the major sources of TMAO, is considered cardioprotective [<a href="#rid76">76</a>].</p><p>TMAO is generated from digestive breakdown of food products that are further metabolized by the liver [<a href="#rid71">71</a>]. Inhibition of intestinal generation of TMAO precursors not only decreased TMAO concentration, but also experimental indicators of atherogenicity [<a href="#rid77">77</a>]. In animal experiments, the pro-atherogenic effect of TMAO could be inhibited by neutralizing intestinal generation of its precursors [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Phosphorus</span><span class="headingEndMark"> — </span>A high serum concentration of phosphates is related to pruritus and hyperparathyroidism, both manifestations of the uremic syndrome [<a href="#rid78">78</a>]. Phosphorus excess also inhibits 1 alpha-hydroxylase and hence the production of calcitriol, the active vitamin D metabolite [<a href="#rid79">79</a>]. Phosphorus retention also alters polyamine metabolism by causing a decrease in intestinal dysfunction and proliferation of intestinal villi [<a href="#rid80">80</a>]. Hyperphosphatemia is also linked to vascular calcification, proinflammatory mechanisms, and klotho deficiency [<a href="#rid81">81</a>]. This mechanism leads to a rise in fibroblast growth factor-23 (FGF-23), a large molecule that increases in concentration early in the course of CKD [<a href="#rid82">82</a>] and has a strong predictive value for negative outcomes in patients on dialysis [<a href="#rid83">83</a>]. In animal studies, FGF-23 can cause cardiac hypertrophy [<a href="#rid84">84</a>] and impaired recruitment of neutrophils in response to infectious stimuli [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Fibroblast growth factor 23'</a>.)</p><p>At least in animals, phosphate restriction has an attenuating effect on the progression of kidney disease. The results are less compelling in humans [<a href="#rid86">86</a>]. However, dietary phosphate restriction reduces parathyroid hormone (PTH) levels over a wide range of serum calcium concentrations [<a href="#rid87">87</a>]. In observational studies, high serum phosphorus is linked to mortality [<a href="#rid88">88</a>].</p><p>Blood phosphorus concentration is the result of protein catabolism and protein intake, as well as of the ingestion of other dietary sources.</p><p>The effect of oral phosphate binders is often insufficient, especially in subjects with high intake. One major effect related to hyperphosphatemia is the increase in Ca deposition in the tissues, especially the vessel wall [<a href="#rid88">88</a>], which is a negative prognostic factor in patients with CKD [<a href="#rid89">89</a>]. This does not exclude the individual roles of both Ca and P in vascular disease of CKD [<a href="#rid90">90</a>]. Application of calcium-containing intestinal phosphate binders may decrease P, but this effect may be counterbalanced by a rise in Ca [<a href="#rid91">91</a>].</p><p>The newer generation of phosphate binders, such as <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">sevelamer</a> and <a class="drug drug_general" data-topicid="10219" href="/z/d/drug information/10219.html" rel="external">lanthanum</a>, may provide a solution to this problem [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Treatment approach'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Hydrogen ions</span><span class="headingEndMark"> — </span>Metabolic acidosis can contribute to some of the abnormalities in ESKD. Metabolic acidosis can cause muscle wasting and bone mineral loss and, in children, impair growth [<a href="#rid93">93,94</a>]. (See  <a class="medical medical_review" href="/z/d/html/2293.html" rel="external">"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">PROTEIN-BOUND COMPOUNDS</span></p><p class="headingAnchor" id="H14"><span class="h2">P-cresol and p-cresyl sulfate</span><span class="headingEndMark"> — </span>P-cresol, a phenol with a molecular weight of only 108 daltons, has been considered the prototype of lipophilic, uremic, protein-bound toxins. Because of strong protein binding, removal of such compounds by classical dialysis is hampered [<a href="#rid95">95,96</a>]; each hemodialysis session removes only a fraction of p-cresyl sulfate compared to the normal kidneys [<a href="#rid97">97</a>]. It is therefore conceivable that alternative removal methods (eg, adsorption or convective transport) should be developed before adequate elimination of such toxins can be obtained [<a href="#rid98">98,99</a>].</p><p>Evidence underscores that conjugates of p-cresol, p-cresyl sulfate and p-cresyl glucuronate, and not p-cresol per se, are present in the blood of patients with chronic kidney disease (CKD) [<a href="#rid96">96,100</a>]. Previous repeated measurements of p-cresol in body fluids were related to the fact that most determination methods applied strong acidification for deproteinization, a measure resulting in deconjugation of p-cresyl sulfate and p-cresyl glucuronate by hydrolysis [<a href="#rid101">101,102</a>]. Since this hydrolysis is conceivably proportional to the quantity of conjugates available, former p-cresol measurements as well as estimations of protein binding are likely proportional to what would have been found by direct measurement of the conjugates.</p><p>High-flux dialysis, compared with low-flux dialysis, has no beneficial effect on the removal of these toxins [<a href="#rid95">95,98</a>]. However, compared with peritoneal dialysis, p-cresol is cleared better with high-flux hemodialysis [<a href="#rid103">103</a>]. Nevertheless, the plasma concentrations of protein-bound toxins are lower in patients on peritoneal dialysis compared with those on hemodialysis [<a href="#rid103">103,104</a>]; these findings cannot be explained by differences in dietary protein intake or residual kidney function, suggesting a role for metabolism and/or intestinal handling [<a href="#rid105">105</a>].</p><p>P-cresol is an end product of protein catabolism, produced by intestinal bacteria that metabolize tyrosine and phenylalanine [<a href="#rid106">106</a>]. Environmental sources of p-cresol are toluene, menthofuran, and cigarette smoke. Specific concern is warranted regarding menthofuran, which is present in several herbal medicines, flavoring agents, and psychedelic drugs [<a href="#rid107">107</a>]. In view of the known role of the intestine in the generation of p-cresol and its conjugates, several approaches that interfere with intestinal generation of these toxins have been studied and shown to decrease their concentration [<a href="#rid108">108</a>]. (See <a class="local">'General removal strategies'</a> below.)</p><p>In several studies, p-cresol concentration was related to parameters of clinical outcome, including hospitalization rate (particularly due to infection) [<a href="#rid102">102</a>], clinical symptoms of the uremic syndrome [<a href="#rid101">101</a>], mortality [<a href="#rid109">109</a>], and cardiovascular disease [<a href="#rid110">110,111</a>]. The same associations were also demonstrated with p-cresyl sulfate [<a href="#rid112">112,113</a>] and existed among patients with earlier stages of CKD (CKD 2 to 4) [<a href="#rid114">114</a>]. The latter observation suggests that protein-bound solutes may also exert a toxic effect in those not affected by marked kidney disease. In a prospective, observational analysis, p-cresyl sulfate and indoxyl sulfate were independently associated with progression of CKD [<a href="#rid115">115</a>]. A meta-analysis confirmed the negative association of p-cresyl sulfate with hard outcomes [<a href="#rid116">116</a>]. In a study comparing the prognostic weight of several protein-bound uremic toxins, p-cresyl sulfate was the best independent overall predictor of overall mortality and cardiovascular mortality, even after adjustment for estimated glomerular filtration rate (eGFR) [<a href="#rid117">117</a>].</p><p>The number of data underscoring the biochemical (toxic) effect of the conjugates is steadily growing [<a href="#rid118">118</a>]. Of note, in most studies, correct concentrations were applied while also taking into account the effect of protein binding. In one study, it was demonstrated that p-cresyl sulfate stimulated baseline leukocyte activity, thereby pointing to a proinflammatory effect, whereas the parent compound p-cresol essentially inhibited activated leukocyte function [<a href="#rid119">119</a>]. Another study found that retained p-cresol and p-cresyl sulfate altered endothelial function [<a href="#rid120">120</a>]. Several studies showed effects related to tubular damage and progression of kidney dysfunction, such as an enhanced expression of cytokine and inflammatory genes in proximal tubular cells [<a href="#rid121">121</a>], epithelial mesothelial transition, fibrosis, and glomerulosclerosis through the activation of the renin-angiotensin-aldosterone system [<a href="#rid122">122</a>] and suppression of klotho gene expression leading to fibrosis [<a href="#rid123">123</a>]. Oxidative stress damage has been demonstrated in rat tubular cells [<a href="#rid124">124</a>], and the induction of insulin resistance and reallocation of adipose cells has been demonstrated in different tissues [<a href="#rid125">125</a>]. The leukocyte-activating impact of p-cresyl sulfate has been demonstrated in whole human blood [<a href="#rid126">126</a>]. In one study, the second conjugate, p-cresyl glucuronide, combined with p-cresyl sulfate, had an additive effect on leucocyte oxidative burst activity [<a href="#rid126">126</a>]. P-cresyl sulfate, administered peritoneally or intravenously, increased rolling of leukocytes along the endothelium of peritoneal vessels, as directly visualized by in vivo microscopy, and p-cresyl sulfate and p-cresyl glucuronide induced vascular leakage for albumin [<a href="#rid127">127</a>]. These data suggest a direct toxic effect of these molecules on vascular endothelium and an induction of the cross-talk between vascular endothelium and leukocytes, which is a primary step of a chain of events leading to vascular damage.</p><p>The concern has been expressed that, even if correct uremic concentrations were applied in studies on protein-bound toxins, the (near) absence of albumin may have resulted in an increased percentage of non-protein-bound fraction, which is the fraction that exerts biological activity [<a href="#rid128">128</a>]. However, in a systematic review that was limited to experimental studies that used correct free concentrations of p-cresyl sulfate, several studies confirmed the biological effects of p-cresyl sulfate at uremia-relevant concentrations [<a href="#rid129">129</a>]. The analysis, which also included studies on indoxyl sulfate, in total included 27 publications, of which several complied with high-quality standards.</p><p>Although the conjugates are present in the blood stream, it remains unclear whether, under some conditions, they may not be reconverted to p-cresol intracellularly, especially since certain cell types such as the leukocytes contain sulfatases and glucuronidases.</p><p>Previously, only a few studies that examined how to improve removal of the phenols by extracorporeal strategies were performed. One study showed superior dialytic clearance of p-cresol by high-flux hemodialysis compared with peritoneal dialysis [<a href="#rid103">103</a>], although, as noted previously, plasma concentrations were lower in peritoneal dialysis patients [<a href="#rid105">105</a>]. Among dialysis strategies, convective approaches were more efficient compared with diffusive ones [<a href="#rid130">130-132</a>]. In another study, increasing dialysate flow and dialyzer surface area while decreasing blood flow in an extended dialysis setting increased removal of protein-bound solutes without altering Kt/V [<a href="#rid133">133</a>]. However, as compared with standard, four-hour dialysis three times per week, a longer session (eight-hour dialysis) three times per week had no significant impact on protein-bound solute concentration; this was in contrast to observations with small, water-soluble compounds and middle molecules [<a href="#rid134">134</a>]. However, a nonsignificant trend for increased removal of protein-bound molecules was observed in this study. In contrast, if hemodialysis was extended without decreasing blood or dialysate flow as compared with standard, a significant increase in removal with extended dialysis could be observed [<a href="#rid135">135</a>].</p><p>Removal could be markedly enhanced by applying combined fractionated plasma separation and adsorption, a strategy used by an artificial liver (Prometheus) [<a href="#rid136">136</a>]. Unfortunately, the approach applied in this study resulted in major coagulation disturbances [<a href="#rid137">137</a>]. However, the study offers proof of concept that adsorption may become an additional asset in the removal of this type of compound. In an in vitro setting, embedding adsorptive material on a high-flux membrane markedly enhanced the removal capacity for protein-bound toxins [<a href="#rid99">99,138</a>].</p><p>As far as convective strategies are concerned, it was shown that postdilution and predilution hemodiafiltration were not different regarding removal of p-cresyl sulfate. Both hemodiafiltration strategies were superior to predilution hemodiafiltration for p-cresyl sulfate and other protein-bound compounds, whereas postdilution hemodiafiltration was superior to predilution hemodiafiltration for all other types of uremic retention solutes (ie, the small, water-soluble compounds and the larger "middle molecules") [<a href="#rid139">139</a>].</p><p>The cresols, as several other protein-bound toxins, are the end product of metabolic transformation of amino acids by the intestinal microbiome and by conjugation processes in the intestinal wall or liver [<a href="#rid108">108</a>]. In advanced chronic kidney disease, the microbiome appears to be modified in favor of species that generate these uremic toxins [<a href="#rid140">140</a>], though studies examining the association between kidney dysfunction and urinary excretion of p-cresol report conflicting results [<a href="#rid141">141,142</a>].</p><p>There are studies suggesting that intestinal bacterial production and/or intestinal uptake of p-cresol can be altered. As an example, prevention of the intestinal absorption of p-cresol by administration of oral sorbents (AST-120) decreased its serum concentration [<a href="#rid143">143</a>]. In a metabolomic study in rats, the same sorbent decreased the concentration of a host of mainly protein-bound uremic solutes, including p-cresyl sulfate [<a href="#rid144">144</a>]. In addition, the prebiotic arabino-xylo-oligosaccharide (AXOS) decreased p-cresyl sulfate in mice, while decreasing its biochemical impact mainly related to insulin resistance [<a href="#rid125">125</a>]. However, in a mouse model of CKD, <a class="drug drug_general" data-topicid="10261" href="/z/d/drug information/10261.html" rel="external">sevelamer</a> hydrochloride administration had no impact on the concentration of any of the protein-bound compounds [<a href="#rid145">145</a>], and the same was observed in a subsequent study in humans [<a href="#rid146">146</a>]. A subsequent randomized controlled trial (RCT) in patients with nondialysis CKD, however, did show a decrease induced by sevelamer [<a href="#rid147">147</a>].</p><p>Dietary intake may alter the generation of p-cresyl sulfate. In one study of 26 individuals with normal kidney function, the average p-cresyl sulfate excretion (reflecting generation) was 62 percent lower among vegetarians than among participants on an unrestricted diet [<a href="#rid148">148</a>]. A metabolomic comparison between hemodialysis patients with and without colon showed striking differences in protein-bound and other uremic toxin concentrations, including p-cresyl sulfate [<a href="#rid149">149</a>].</p><p>The quality of studies assessing interventions to modify the intestinal microbiome or its metabolism in CKD is poor [<a href="#rid150">150</a>], and hard outcome studies remain scarce [<a href="#rid150">150</a>]. A randomized, controlled trial on dietary fiber supplementation showed a decrease in indoxyl sulfate concentration but not in p-cresyl sulfate [<a href="#rid151">151</a>]. In another randomized, controlled trial, administration of a symbiotic resulted in a decrease of p-cresyl sulfate concentration, especially in patients who received no antibiotics during the course of the study [<a href="#rid152">152</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Homocysteine</span><span class="headingEndMark"> — </span>Homocysteine (Hcy) is a sulfur-containing amino acid produced by the demethylation of methionine. Its retention with uremia results in the cellular accumulation of S-adenosyl homocysteine (AdoHcy), an extremely toxic compound that competes with S-adenosyl-methionine (AdoMet) and inhibits methyltransferases [<a href="#rid153">153</a>]. Patients with CKD have total serum Hcy levels two- to fourfold above those observed in normal individuals. In addition to the degree of kidney dysfunction, its serum concentration also depends upon nutritional intake (eg, of methionine), vitamin status (eg, of folate), and genetic factors.</p><p>The association of hyperhomocysteinemia with vascular disease is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6837.html" rel="external">"Overview of homocysteine"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Tryptophan metabolites</span><span class="headingEndMark"> — </span>Indoxyl sulfate is metabolized by the liver from indole, which is produced by the intestinal microbiome as a metabolite of tryptophan. Indoxyl sulfate, which is secreted in the normal kidney by organic anion transporter 3 [<a href="#rid154">154</a>], enhances drug toxicity by competition with acidic drugs at protein-binding sites [<a href="#rid155">155</a>] and inhibits the active tubular secretion of these compounds as well as the deiodination of thyroxine 4 (T4) by cultured hepatocytes [<a href="#rid156">156,157</a>].</p><p>Uremic retention solutes induce glomerular sclerosis [<a href="#rid158">158</a>], with their removal by peritoneal dialysis or by oral sorbent administration retarding the progression of intact nephron loss. Indoxyl sulfate may be one of these possible uremic toxins. The oral administration of indole or of indoxyl sulfate to uremic rats causes a faster progression of glomerular sclerosis and kidney dysfunction [<a href="#rid159">159,160</a>]. In renal tubular cells, indoxyl sulfate induces free radical production, nuclear factor kappa B (NF-kappaB) activation, and upregulation of plasminogen activator inhibitor-1 (PAI-1) expression [<a href="#rid161">161</a>]. Studies cited above demonstrated indoxyl sulfate-associated enhanced expression of cytokine and inflammatory genes [<a href="#rid121">121</a>], epithelial mesothelial transition, fibrosis and glomerulosclerosis through the activation of the renin-angiotensin-aldosterone system [<a href="#rid122">122</a>], and suppression of klotho gene expression leading to fibrosis [<a href="#rid123">123</a>].</p><p>Among patients on peritoneal dialysis, indoxyl sulfate was correlated with interleukin (IL)-6 [<a href="#rid162">162</a>]. Risk factors of atherosclerosis are associated with indoxyl sulfate concentration in patients on hemodialysis [<a href="#rid163">163</a>]. In a study that included patients with CKD stages 2 to 5, serum indoxyl sulfate was predictive of mortality, even after adjustment for major cardiovascular risk factors [<a href="#rid164">164</a>]. However, in a multifactorial analysis, the significance of its association with outcomes was inferior to that of p-cresyl sulfate [<a href="#rid117">117</a>].</p><p>Endothelial cell dysfunction is common in uremia. Indoxyl sulfate may play a role by inhibiting endothelial cell proliferation and repair [<a href="#rid165">165</a>], while it induces a significant production of free radical species in endothelial cells [<a href="#rid166">166,167</a>]. Endothelial dysfunction induced by indoxyl sulfate is also illustrated by an increase in microparticle release by cultured endothelial cells [<a href="#rid168">168</a>]. Endothelial-leukocyte interaction, resulting in leukocyte adhesion to the endothelial wall, is also activated [<a href="#rid169">169</a>]. In a rat model, indoxyl sulfate stimulates vascular smooth muscle cell proliferation [<a href="#rid170">170</a>]. Indoxyl sulfate also has direct profibrotic, prohypertrophic, and proinflammatory effects on cardiac fibroblasts and myocytes [<a href="#rid171">171</a>].</p><p>It has been suggested that indoxyl sulfate plays a role in aortic calcification [<a href="#rid172">172</a>] and elements of bone dysfunction, such as resistance to parathyroid hormone (PTH), osteoblast dysfunction, and downregulation of pathways of PTH gene expression and low-turnover bone disease [<a href="#rid173">173-175</a>].</p><p>A thrombogenic effect has also been attributed to indoxyl sulfate, essentially by the demonstration of interference with the generation of thrombogenesis tissue factor 3 via the aryl hydrocarbon receptor pathway [<a href="#rid176">176-178</a>].</p><p>In one study, indoxyl sulfate was shown to enhance adhesion and extravasation of leukocytes to the same degree as lipopolysaccharide, as well as to cause an almost total stagnation of blood flow within the studied vessels [<a href="#rid127">127</a>]. In an attempt to unravel the mechanism of these profound alterations, it was shown that, in the presence of indoxyl sulfate, the glycocalyx, a molecular layer protecting the endothelium, was affected. Heparan sulfate, one of the main components of the glycocalyx, was found in increased concentration in the serum of indoxyl sulfate-treated rats. Of note, a study had shown in a similar way increased free-floating heparan sulfate in the plasma of hemodialysis patients [<a href="#rid179">179</a>].</p><p>A systematic review that included multiple studies revealed an overall negative biochemical impact of indoxyl sulfate [<a href="#rid129">129</a>]. This was also observed with p-cresyl sulfate (see <a class="local">'P-cresol and p-cresyl sulfate'</a> above). The data contained in the systematic review are of interest in function of the ongoing discussion that many toxicity studies on protein-bound uremic toxins, of which indoxyl sulfate is a prototype, have been biased by the application of too high concentrations, especially free non-protein-bound concentrations. All 27 studies included in that systematic review had been performed at correct concentrations. The review pointed to biologic effects that all could be linked to vascular damage and progression of kidney failure.</p><p>Studies published subsequent to this systematic review and also applying the correct concentrations point to suppression of erythropoietin production [<a href="#rid180">180</a>], monocyte transition into profibrotic macrophages [<a href="#rid181">181</a>], suppression of neovascularization [<a href="#rid182">182</a>], suppression of fetuin-A expression [<a href="#rid183">183</a>], vascular inflammation via activation of the aryl hydrocarbon receptor [<a href="#rid184">184</a>], vascular functional disturbances [<a href="#rid185">185</a>], and cognitive impairment [<a href="#rid186">186</a>]. Many of these studies point to a central role of the aryl hydrocarbon receptor [<a href="#rid178">178,180,184,186</a>].</p><p>That biological effects of indoles are not restricted to indoxyl sulfate was demonstrated in a study showing that indole-3-acetic acid activated the inflammatory nongenomic aryl hydrocarbon receptor (AhR)/p38MAPK/NF-kappaB pathway, hence inducing the proinflammatory enzyme cyclooxygenase-2 [<a href="#rid187">187</a>]. A clinical arm of this study also showed a higher mortality among patients with the highest indole-3-acetic acid levels [<a href="#rid187">187</a>]. Other studies demonstrated a proinflammatory and a procoagulant effect [<a href="#rid176">176,188,189</a>]. Indole acetic acid has also been associated with kidney damage [<a href="#rid158">158,190</a>] and with osteoblastogenesis [<a href="#rid191">191</a>].</p><p>Another group of toxic indoles with emerging interest are the <strong>kynurenines</strong>. Kynurenines increase leukocyte adhesion to vascular endothelium [<a href="#rid192">192</a>], activate AhR [<a href="#rid193">193</a>], and decrease production of tumor necrosis factor-alpha (TNF-alpha) [<a href="#rid194">194</a>]. Injections of kynurenic acid in rats with normal kidney function impaired their cognitive flexibility [<a href="#rid195">195</a>]. Furthermore, they also modify metabolic functions [<a href="#rid66">66,196</a>].</p><p>In patients with ESKD, the kynurenines were associated with oxidative stress, inflammation, cardiovascular disease, and hypercoagulability [<a href="#rid197">197,198</a>].</p><p>Indoles are found in various plants and herbs, and a substantial number are produced by the intestinal microbiome. Several metabolites are retained in uremia, and kinetic behavior appears to differ among them. Some of these substances do not even conform to the definition of uremic retention solutes, as their concentration is low in patients with ESKD (eg, tryptophan, melatonin) and/or they have been associated with beneficial biologic effects (eg, indole, indole propionic acid).</p><p>Indoxyl sulfate concentration has been associated to mortality and vascular damage in CKD patients [<a href="#rid164">164</a>] and also with postangioplasty stenosis of vascular access grafts [<a href="#rid199">199</a>]. A meta-analysis accounting for several clinical studies confirmed the negative association of indoxyl sulfate with hard outcomes [<a href="#rid116">116</a>]. [<a href="#rid200">200</a>]</p><p>Removal of protein-bound tryptophan metabolites is hampered during dialysis [<a href="#rid95">95</a>]. It does not correlate with that of urea or creatinine [<a href="#rid201">201</a>]. In conventional hemodialysis, super-flux triacetate membrane was superior to low-flux cellulose triacetate regarding removal of indoxyl sulfate [<a href="#rid202">202</a>]. Convective strategies are superior to diffusion with regards to removal [<a href="#rid132">132,139</a>]. It is, however, questionable whether these rather subtle differences in removal will be sufficient to have a significant impact on solute concentration. Adsorptive removal strategies have the potential to provide added value [<a href="#rid99">99</a>]. In a group of CKD patients not yet on dialysis, the sorbent AST-120 actively decreased indoxyl sulfate in a dose-dependent way, as appreciated from a short-term, prospective, dose-finding study. However, in that study, there were no differences in decline of kidney function [<a href="#rid203">203</a>]. </p><p>As in a prospective, observational analysis, p-cresyl sulfate and indoxyl sulfate were independently associated with progression of CKD [<a href="#rid115">115</a>]. A next logical step was to study the impact of AST-120 on the progression of CKD. In small, controlled studies with a long follow-up period, the group on AST-120 showed a slower decline of eGFR, was started later on dialysis, and survived longer once dialysis was started [<a href="#rid204">204-206</a>]. However, a large American/European randomized, controlled trial could not confirm the beneficial impact of AST-120 on the progression of kidney failure [<a href="#rid207">207</a>]. The study contained no control of whether the group on AST-120 showed a decrease in plasma concentration of protein-bound uremic toxins. Also, in another study, no impact of AST-120 on progression of CKD could be observed, but, in this study, the administration of the sorbent was not associated with a marked decrease in plasma indoxyl sulfate [<a href="#rid208">208</a>].</p><p>Oral administration of bifidobacteria in gastro-resistant capsules to hemodialysis patients, with the intention of modifying the intestinal microbiome, reduces serum levels of indoxyl sulfate and corrects the microbiome balance [<a href="#rid209">209,210</a>]. Dietary intake may also alter serum levels of indoxyl sulfate. In the study cited above of 26 individuals with normal kidney function, the average indoxyl sulfate excretion (reflecting generation) was 58 percent lower among vegetarians than among participants on an unrestricted diet [<a href="#rid148">148</a>]. In a randomized, controlled trial of hemodialysis patients, dietary fiber supplementation induced a decrease in indoxyl sulfate concentration but not in p-cresyl sulfate [<a href="#rid151">151</a>]. In another randomized, controlled trial, administration of a symbiotic resulted in a decrease of p-cresyl sulfate concentration, especially in patients who received no antibiotics during the course of the study [<a href="#rid152">152</a>]. The differences in response between p-cresyl sulfate and indoxyl sulfate might be explained by diverging metabolic pathways in the generation of these two solutes [<a href="#rid211">211</a>].</p><p>Kidney transplantation decreased indoxyl sulfate to a level that was lower than for nontransplanted subjects with similar kidney function [<a href="#rid212">212</a>]. Also, in patients with acute kidney injury (AKI), serum indoxyl sulfate concentrations were lower than in patients with CKD and similar kidney function [<a href="#rid213">213</a>]. These findings suggest an impact of other factors in addition to kidney function (eg, intestinal metabolism). </p><p class="headingAnchor" id="H17"><span class="h2">Furanpropionic acid</span><span class="headingEndMark"> — </span>3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF), a urofuranic fatty acid, is a strongly lipophilic uremic solute and a major inhibitor of drug protein binding [<a href="#rid156">156</a>]. This toxin inhibits the kidney uptake of para-amino hippuric acid (PAH) in rat kidney cortical slices [<a href="#rid214">214</a>] and causes a decrease in renal excretion of various drugs, metabolites, and endogenously produced organic acids that are removed via the PAH pathway. In vivo kidney CMPF clearance in the rat is inhibited by PAH and <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> [<a href="#rid215">215</a>]. CMPF also inhibits hepatic glutathione-S-transferase [<a href="#rid216">216</a>], deiodination of T4 by cultured hepatocytes [<a href="#rid157">157</a>], and adenosine diphosphate (ADP)-stimulated oxidation of nicotinamide adenine dinucleotide (NADH)-linked substrates in isolated mitochondria [<a href="#rid217">217</a>]. CMPF has been related to inhibition of insulin secretion from pancreatic islets [<a href="#rid218">218,219</a>] but in other studies has been shown to inhibit hepatic steatosis [<a href="#rid220">220,221</a>] and via this route insulin resistance [<a href="#rid221">221</a>].</p><p>There is a correlation between neurologic abnormalities and the plasma concentration of CMPF [<a href="#rid222">222</a>]. Since CMPF is almost 100 percent protein bound, its removal by hemodialysis strategies is virtually nonexistent. CMPF levels can be lowered substantially only with peritoneal dialysis [<a href="#rid223">223</a>].</p><p class="headingAnchor" id="H3727854161"><span class="h2">Phenyl acetic acid</span><span class="headingEndMark"> — </span>Phenyl acetic acid has been linked to inhibition of inducible nitric oxide synthase (iNOS) expression [<a href="#rid224">224</a>], osteoblast proliferation and differentiation [<a href="#rid225">225</a>], enhancement of the formation of oxygen-free radicals in vascular smooth muscle cells [<a href="#rid226">226</a>], and increases of inflammatory response by polymorphonuclear leukocytes [<a href="#rid227">227</a>]. It also inhibits renal cellular solute transport pumps [<a href="#rid228">228</a>] and conjugation by glucuronidation [<a href="#rid66">66</a>]. Finally, in a clinical study, phenyl acetic acid was related to cognitive dysfunction in dialysis patients [<a href="#rid229">229</a>].</p><p class="headingAnchor" id="H18"><span class="h1">MIDDLE MOLECULES</span><span class="headingEndMark"> — </span>Middle molecules, arbitrarily defined as those of a molecular weight in excess of 500 daltons, were previously thought responsible for the uremic syndrome. However, at the time of the formulation of the middle-molecule hypothesis, it was extremely difficult to isolate specific responsible molecules.</p><p>Nevertheless, several clinical, metabolic, and/or biochemical disturbances are caused by uremic compounds with molecular weights in this middle-molecule range:</p><p class="bulletIndent1"><span class="glyph">●</span>Chromatographic fractions of uremic ultrafiltrate with a molecular weight between 1 and 5 kD inhibit appetite and suppress food intake in animals [<a href="#rid230">230</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 500 to 2000 dalton subfraction of uremic serum inhibits apolipoprotein (apo) A-I secretion in a human hepatoma cell line [<a href="#rid231">231</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A compound of molecular weight between 750 and 900 daltons inhibits osteoblast mitogenesis [<a href="#rid232">232</a>].</p><p></p><p>A substantial number of compounds have been identified that conform to the strict definition of middle molecules [<a href="#rid7">7,8,11,233</a>]. Several of those have biological effects and especially affect vascular wall integrity by causing inflammation, coagulation, endothelial damage, or smooth muscle cell proliferation [<a href="#rid2">2</a>].</p><p>A variety of dialytic strategies increase removal of middle molecules, such as the use of high-flux dialysis membranes, hemodiafiltration, and medium cut-off (MCO) dialyzers. The potential clinical impact of such strategies is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis", section on 'Hemodialysis membranes'</a> and  <a class="medical medical_review" href="/z/d/html/1937.html" rel="external">"Alternative kidney replacement therapies in end-stage kidney disease", section on 'Clinical effects of convective therapies'</a> and  <a class="medical medical_review" href="/z/d/html/1887.html" rel="external">"Overview of the hemodialysis apparatus", section on 'Flux'</a>.) [<a href="#rid234">234-237</a>]</p><p class="headingAnchor" id="H19"><span class="h2">Beta2-microglobulin</span><span class="headingEndMark"> — </span>Beta2-m (molecular weight of approximately 12,000 D) is a component of the major histocompatibility antigen (see  <a class="medical medical_review" href="/z/d/html/3969.html" rel="external">"Major histocompatibility complex (MHC) structure and function"</a>). Dialysis-related amyloid, which can be observed in patients being maintained on long-term dialysis, is to a large extent composed of beta2-m. Nevertheless, some patients may suffer from amyloidosis after only one to two years of dialysis [<a href="#rid238">238,239</a>]. Dialysis-related amyloidosis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1983.html" rel="external">"Dialysis-related amyloidosis"</a>.)</p><p>In a proteomic analysis searching for biomarkers for peripheral vascular disease in a population reportedly without major kidney dysfunction, beta2-m was the only discriminator, suggesting a potential link to the development of vascular disease [<a href="#rid240">240</a>].</p><p>Beta2-m has also been shown to impair cognitive function and act as a pro-aging factor [<a href="#rid241">241</a>]. It has also been associated with itching [<a href="#rid242">242</a>] and frailty [<a href="#rid243">243</a>]. However, no activation of circulating leukocytes could be observed in the presence of uremic concentrations of beta2-m in an in vitro study [<a href="#rid244">244</a>]. This does not exclude other biological actions of that molecule. Beta2-m fibrils affect function and/or viability of osteoblasts, osteoclasts, and chondrocytes [<a href="#rid245">245</a>]. An in vitro study showed a link between beta2-m and modifications in the erythrocyte plasma membrane, with the potential to affect cell shape and removal from the circulation [<a href="#rid246">246</a>]. In vivo and in vitro experimental studies showed an impact on osteoclast formation [<a href="#rid247">247</a>] and upregulation of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 generation [<a href="#rid247">247</a>], epithelial-to-mesenchymal transition [<a href="#rid248">248</a>], and neurotoxicity [<a href="#rid249">249</a>].</p><p>Advanced glycosylation end products (AGEs) may affect the pathophysiologic impact of beta2-m. AGE-modified beta2-m has been identified in amyloid of hemodialyzed patients [<a href="#rid250">250</a>]; it also enhances monocytic migration and cytokine secretion [<a href="#rid251">251</a>], suggesting that foci containing AGE beta2-m may initiate inflammatory response, leading to bone/joint destruction [<a href="#rid250">250,251</a>].</p><p>Serum beta2-m levels may be lower in peritoneal dialysis patients than in hemodialysis patients [<a href="#rid252">252</a>]. This may be due to a better conservation of endogenous residual kidney function with peritoneal dialysis since peritoneal dialysis alone poorly clears beta2-m [<a href="#rid103">103</a>]. Although the clinical expression of dialysis-related amyloidosis disappears after kidney transplantation, the underlying pathologic processes, such as bone cysts and tissue beta2-m deposits, remain [<a href="#rid253">253</a>].</p><p>In prospective studies, a progressive decline of predialysis beta2-m levels has frequently been demonstrated in patients dialyzed with membranes with a larger pore size [<a href="#rid254">254</a>]. The question arises whether this removal is sufficient to prevent the development of beta2-m amyloid. In a retrospective study, AN69 dialyzers with a large pore size were associated with a lower prevalence of amyloid disease than small-pore cuprophane [<a href="#rid255">255</a>]. However, cuprophane also induces a more profound inflammatory reaction, which is known to enhance the development of amyloid disease.</p><p>Finally, a post-hoc analysis of the HEMO study found that serum beta2-m levels correlated with mortality, with each 10 mg/L increase in predialysis level being associated with an 11 percent increase for all-cause mortality [<a href="#rid256">256</a>]. Later analysis revealed that this mortality was related to infectious causes [<a href="#rid257">257</a>]. This result may lend support to using beta2-m levels as a marker for middle-molecule clearance. These data may, however, have been confounded by residual kidney function, selection bias, and inflammation.</p><p class="headingAnchor" id="H20"><span class="h2">Parathyroid hormone</span><span class="headingEndMark"> — </span>Parathyroid hormone (PTH), a middle molecule with a molecular weight of approximately 9000 daltons, is generally recognized as a major uremic toxin. However, its increase in concentration during end-stage kidney disease (ESKD) is attributable to enhanced glandular secretion rather than to decreased removal by the kidneys. Excess PTH gives rise to an increase in intracellular calcium, resulting in disturbances in the function of virtually every organ system [<a href="#rid258">258</a>].</p><p>A downregulation of PTH/PTHrP receptor mRNA expression is observed in the liver, kidney, and heart of rats with advanced chronic kidney disease (CKD), thereby blunting the cellular response to excess PTH and creating resistance to PTH [<a href="#rid259">259</a>]. Parathyroidectomy does not entirely prevent PTH/PTHrP receptor downregulation [<a href="#rid260">260</a>], suggesting that this alteration depends on more than elevated PTH alone.</p><p>The increased PTH concentration in uremia is the result of a number of compensatory homeostatic mechanisms. Hyperparathyroidism results at least in part from phosphate retention, decreased production of calcitriol (1,25-dihydroxyvitamin D), and hypocalcemia. (See  <a class="medical medical_review" href="/z/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.) </p><p class="headingAnchor" id="H21"><span class="h2">Advanced glycosylation end products</span><span class="headingEndMark"> — </span>The role of AGEs in CKD has extensively been reviewed [<a href="#rid261">261</a>]. Glucose and other reducing sugars react nonenzymatically with free amino groups to be converted after weeks into AGEs through chemical rearrangements and dehydration reactions [<a href="#rid262">262</a>]. Several AGE compounds are peptide-linked degradation products (molecular weight 2000 to 6000 D) [<a href="#rid263">263</a>]. Among the postulated structures for AGE are glyoxal, methylglyoxal, imidazolone, pyrrole aldehyde, pentosidine, and N epsilon-(carboxymethyl)lysine.</p><p>The increased accumulation of AGE in CKD is not only the result of enhanced glucose levels or reduced removal of modified proteins by glomerular filtration. With uremia, it is also likely due to increased concentrations of small carbonyl precursors and inflammation. Thus, uremia can be described as a status of increased carbonyl stress, resulting from increased oxidation or decreased detoxification of these carbonyl compounds [<a href="#rid264">264</a>]. Together, these processes result in increased levels of AGEs [<a href="#rid264">264</a>].</p><p>AGEs affect multiple processes [<a href="#rid261">261</a>]. These compounds:</p><p class="bulletIndent1"><span class="glyph">●</span>Cause an inflammatory reaction in monocytes by the induction of IL-6, TNF-alpha, and interferon-gamma [<a href="#rid265">265</a>]. Proinflammatory effects had previously been demonstrated with artificially prepared AGEs. A similar proinflammatory impact was present with genuine AGEs as they were accumulated in uremia [<a href="#rid266">266</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modify beta2-m, which (as previously mentioned) may play an important role in the formation of dialysis-related amyloid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>React with and chemically inactivate nitric oxide (NO), a potent endothelium-derived vasodilator, antiaggregant, and antiproliferative factor [<a href="#rid267">267</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Induce oxidative protein modification [<a href="#rid268">268</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cause kidney fibrosis [<a href="#rid269">269</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Promote thrombogenicity [<a href="#rid270">270</a>], bone disease, [<a href="#rid271">271</a>] and neurotoxicity [<a href="#rid272">272</a>].</p><p></p><p>In addition to kidney dysfunction, AGEs are also retained in diabetes mellitus and aging, settings in which they have been implicated in tissue damage and functional disturbances. Specific receptors for AGEs have also been identified (RAGE), with their expression already enhanced during moderate uremia [<a href="#rid273">273</a>].</p><p>However, it is unclear whether all AGEs retained in uremia have a biological impact. It is also unknown whether one AGE is kinetically representative for the molecules of the group. Pentosidine has been advanced as a marker for these compounds; however, with respect to dialysis, inhomogeneous behavior of pentosidine has been demonstrated, a finding that parallels what is known for uremic toxins in general [<a href="#rid274">274</a>]. In an observational study, high, rather than low, carboxymethyllysine levels were linked to better outcomes [<a href="#rid275">275</a>].</p><p>This group of molecules highlights growing interest to dialytically remove more of the larger molecules that are retained in uremia, perhaps including more specific removal via adsorption columns.</p><p>Removal is also more efficient with membranes with a larger pore size [<a href="#rid276">276</a>]. This includes protein-leaking dialyzers [<a href="#rid277">277</a>]. This was shown in one study in which two groups of 13 hemodialysis patients were treated for six months with protein-leaking and non-protein-leaking dialyzers [<a href="#rid277">277</a>]. A significant decrease in total pentosidine values was observed with the protein-leaking dialyzer (-43 percent), a decrease not observed with the other dialyzer.</p><p>This removal could counterbalance some of the deleterious effects of AGE accumulation (eg, apolipoprotein B production) [<a href="#rid278">278</a>]. Whether this removal will be sufficient to neutralize the clinical complications potentially attributed to the AGEs is unclear.</p><p>Several nondialytic therapeutic approaches to reduce AGE load have achieved variable success, such as crosslink breakers and AGE-receptor inhibitors [<a href="#rid261">261</a>]. Studies with a glyoxylase-1 activator showed a decrease of methylglyoxal and an increase in insulin sensitivity [<a href="#rid279">279</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Other middle molecules</span><span class="headingEndMark"> — </span>Several peptides of molecular weight above 12 kD, which can be recovered from uremic sera, ultrafiltrate, or peritoneal dialysis dwell fluid, dampen various polymorphonuclear cells functions involved in the killing of invading bacteria [<a href="#rid280">280,281</a>]. The exact concentrations in uremic sera or biological fluids were not reported in these studies.</p><p>Leptin, a 16 kD plasma protein that suppresses appetite [<a href="#rid282">282</a>] and induces weight reduction in mice [<a href="#rid283">283</a>], is retained in kidney dysfunction [<a href="#rid284">284</a>]. The increase in serum leptin levels is almost entirely due to a rise in free (non-protein-bound) concentration [<a href="#rid284">284</a>]; it has been suggested to play a role in the decreased appetite of uremic patients (see  <a class="medical medical_review" href="/z/d/html/1856.html" rel="external">"Pathogenesis and treatment of malnutrition in patients on maintenance hemodialysis"</a>). However, there are conflicting findings concerning the possible biochemical role of leptin in kidney dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased leptin is associated with low protein intake and loss of lean tissue [<a href="#rid285">285</a>]. Data suggest an inverse correlation in uremia between leptin and indices of nutritional status such as serum albumin or lean body mass [<a href="#rid286">286</a>] and a direct correlation with C-reactive protein (CRP) [<a href="#rid287">287</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, leptin levels are also elevated in obese people and are not necessarily related to reduced appetite. Body fat and serum leptin correlate positively in uremia [<a href="#rid287">287</a>].</p><p></p><p>The dinucleoside polyphosphates are molecules characterized by the presence of two nucleotides at the extremes, linked by a variable number (mostly two to six) of phosphates. They have a molecular weight of approximately 1000 daltons and are protein bound. The diadenosine polyphosphates induce proliferation of smooth muscle cells [<a href="#rid288">288,289</a>] and enhance free radical production by leukocytes [<a href="#rid290">290</a>]. Uridine adenosine tetraphosphate is a strong vasoconstrictor, which is released by endothelium [<a href="#rid291">291</a>].</p><p>Fibroblast growth factor-23 (FGF-23) is mostly considered as a regulator of calcium/phosphate metabolism associated with outcome parameters [<a href="#rid292">292</a>] but also has a direct biological impact by inducing left ventricular hypertrophy [<a href="#rid84">84</a>] and leukocyte dysfunction [<a href="#rid85">85</a>].</p><p>Further middle molecules of potential importance are complement factor D, adrenomedullin, atrial natriuretic peptide (ANP), resistin, immunoglobulin light chains, neuropeptide Y, and various cytokines. Plasma IL-6 is independently associated with mortality in patients with CKD [<a href="#rid293">293</a>]. In vitro, however, neither IL-6 nor any of the other major cytokines induced leukocyte activation at concentrations observed in dialysis patients [<a href="#rid294">294</a>]. The only cytokine that produced an effect was TNF-alpha, however, only at high concentrations, which are no longer observed with dialysis strategies employed today. On the other hand, blockade of the interleukin-6 receptor in clinical studies significantly reduced cardiovascular risk [<a href="#rid295">295</a>].</p><p class="headingAnchor" id="H2556044454"><span class="h1">LARGE MOLECULES</span><span class="headingEndMark"> — </span>Newer classifications of uremic toxins have added larger molecules as a novel category [<a href="#rid9">9</a>]. The term refers to molecules with a molecular weight above 58,000 daltons (ie, above the cut-off value of the pores of the kidney glomerular basement membrane). Thus, kidney insufficiency has not much impact on their concentration, but their biological impact may be affected by post-translational modifications of their structure due to uremic conditions. These large molecules include albumin, lipoproteins, or other proteins that may be linked to a variety of smaller moieties that accumulate in patients with impaired kidney function. Examples of such ligands are malondialdehyde, guanidines (including symmetric dimethylarginine), or carbonyl compounds [<a href="#rid296">296</a>]. </p><p class="headingAnchor" id="H23"><span class="h1">GENERAL REMOVAL STRATEGIES</span><span class="headingEndMark"> — </span>The main strategies that have been used to decrease uremic solute concentration are conventional hemodialysis and peritoneal dialysis. However, dialysis is nonspecific and also removes essential compounds. In addition, lipophilic compounds, which may be responsible at least in part for functional alterations in uremia, are inadequately removed by current dialysis strategies. Finally, the complex multicompartmental behavior of uremic toxins results in the removal of only a small fraction of the solutes that are accumulated in the body. </p><p>With maintenance hemodialysis, treatment with high-flux membranes was suggested to provide superior removal of middle molecules, possibly resulting in improved survival. However, the Hemodialysis (HEMO) study found no overall survival difference with high- versus low-flux membranes at primary analysis [<a href="#rid29">29</a>]. On the other hand, differences were found for the entire cohort in cardiovascular mortality and in the subgroup treated for &gt;3.7 years upon enrollment for overall mortality with secondary analysis [<a href="#rid297">297</a>]. In the same database, a direct relation between beta2-microglobulin (beta2-m) concentration and mortality was also demonstrated [<a href="#rid256">256</a>]. In addition, the Membrane Permeability Outcome (MPO) trial subsequently demonstrated better outcomes associated with high-flux compared with low-flux membranes in the population with serum albumin &lt;4 g/dL [<a href="#rid298">298</a>]. Of note, this low serum albumin group composes a large section of the current population on dialysis. (See  <a class="medical medical_review" href="/z/d/html/1847.html" rel="external">"Patient survival and maintenance dialysis", section on 'Hemodialysis membranes'</a> and  <a class="medical medical_review" href="/z/d/html/1887.html" rel="external">"Overview of the hemodialysis apparatus", section on 'Flux'</a>.)</p><p>Adding convection by increasing ultrafiltration and equivoluminous substitution with sterile <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or ultrapure dialysate (hemodiafiltration) adds to middle-molecule removal [<a href="#rid139">139,299-307</a>]. (See  <a class="medical medical_review" href="/z/d/html/1937.html" rel="external">"Alternative kidney replacement therapies in end-stage kidney disease", section on 'Clinical effects of convective therapies'</a>.)</p><p>Compounds may be cleared more efficiently with continuous or long-lasting strategies because removal is more gradual (see  <a class="medical medical_review" href="/z/d/html/1904.html" rel="external">"Technical aspects of nocturnal hemodialysis"</a>). In a strictly comparable setting for all dialysis parameters except treatment length, prolonging high-flux hemodialysis from four to eight hours resulted in a time-dependent increase in beta2-m and phosphorus removal [<a href="#rid308">308</a>]. This implied decreasing blood and dialysis flows in proportion to the increase of dialysis length. However, prolonging hemodialysis did not decrease protein-bound solutes in a similar study [<a href="#rid134">134</a>] unless blood and dialysate flows were kept high [<a href="#rid135">135</a>]. </p><p>Optimal removal for individual types of molecules may be obtained with different types of extracorporeal treatment (eg, by using large-pore membranes and/or dialyzers or devices with a high adsorptive capacity for some or several of the uremic toxins). This includes, for example, protein-leaking membranes, which are designed to allow passage of albumin, other similarly sized proteins, and uremic toxins in the 35 to 60 kD size range [<a href="#rid309">309</a>].</p><p>Medium cut-off (MCO) dialyzers contain larger pores and remove more middle molecules than high-flux dialyzers, with albumin losses comparable with high-flux hemodiafiltration [<a href="#rid310">310</a>]. They may equal or even surpass removal by hemodiafiltration with classical high-flux membranes, even when used in a hemodialysis mode [<a href="#rid310">310</a>].</p><p>Research centers on alternative measures adding to the removal capacity of classical dialysis. These measures include adsorption [<a href="#rid99">99</a>] or changing the physical conditions within the dialyzer (hemodiafiltration with increased plasma ionic strength) and enhancing the free fraction of protein-bound toxins [<a href="#rid311">311</a>]. Clinical tests with the latter strategy yield discrepant results with regard to protein-bound toxin removal [<a href="#rid312">312</a>].</p><p>Removal is also influenced by intestinal intake (especially for the protein-bound solutes, but also for some small water-soluble compounds such as trimethylamine-N-oxide) and preservation of kidney function [<a href="#rid313">313</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intestinal uptake can be reduced by influencing dietary uptake or by oral administration of absorbents. Approaches that have been shown to result in a decrease in concentration include a low-protein diet [<a href="#rid148">148,314</a>], administration of prebiotics such as resistant starch [<a href="#rid315">315</a>], or probiotics such as <em>Bifidobacterium</em> [<a href="#rid108">108,316</a>]. The active intestinal sorbent AST-120 has essentially been associated with absorption of indoxyl sulfate [<a href="#rid203">203</a>] and subsequent preservation of kidney function, but this substance also absorbs p-cresol as well as other compounds [<a href="#rid143">143,144</a>]. However, in large randomized controlled trials (RCTs), the expected positive impact on progression of kidney function impairment has not been confirmed [<a href="#rid112">112,207</a>]. Administration of a symbiotic resulted in a decrease of p-cresyl sulfate and indoxyl sulfate concentration, especially in patients who received no antibiotics during the course of the study [<a href="#rid152">152</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preservation of residual kidney function may also be an important manner to pursue additional removal of retention solutes. In a number of studies, a correlation was found between concentration of several uremic toxins and residual kidney function [<a href="#rid317">317,318</a>]. This relationship appeared stronger than that to adequacy of dialysis. Many of the uremic retention solutes are secreted in the normal kidneys by the organic acid transporters (OATs) of the renal tubular cells [<a href="#rid319">319</a>]. Enhancing this removal (eg, by applying bioartificial kidneys seeded with living tubular cells) may increase removal of these compounds [<a href="#rid320">320</a>].</p><p></p><p>Metabolic pathways generating uremic toxins also generate beneficial compounds. For example, tryptophan metabolites generate notorious uremic toxins like indoxyl sulfate or the kynurenines, but also beneficial compounds like indole of indole propionic acid [<a href="#rid200">200</a>]. It is conceivable that dialysis as a removal strategy clears all compounds from the blood without distinction between harmful and beneficial compounds. </p><p>Finally, it should be considered that, in uremia, not only strategies decreasing solute concentration are important, but interventions countering their biological impact also play a role [<a href="#rid6">6</a>]. Typically, this can be obtained with already developed drugs, such as angiotensin-converting enzyme (ACE) inhibitors in neutralizing Ca influx due to symmetric dimethylarginine (SDMA) [<a href="#rid321">321</a>], but also with drugs still to be developed and would reach a much broader population than with removal strategies (ie, not only the 0.1 to 0.2 percent of the global population with stage 5 chronic kidney disease [CKD], but all those with stage 3 CKD or more [5 to 10 percent]). Similarly, interventions increasing metabolic degradation of toxic solutes may be considered [<a href="#rid60">60</a>]. Some experimental studies suggest that the concentration of indoxyl sulfate can be decreased by interventions decreasing the activity of sulfotransferase, the enzyme responsible for the sulfation of the parent compound, indole [<a href="#rid322">322</a>].</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>The uremic syndrome is a complex mosaic of clinical alterations that may be attributable to several of the different solutes retained in uremia/chronic kidney disease (CKD). Knowledge about the nature and kinetic behavior of the responsible compounds may help when new therapeutic options are considered in the future.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors affecting uremic retention solutes</strong> – The following factors may interfere with uremic solute concentrations and their impact on biological functions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition to classical sources of uremic solutes such as dietary protein breakdown, alternative sources such as environmental contact, food additives, natural stimulants (coffee, tea), intake of herbal medicines, or addiction to psychedelic drugs may play a role in uremic toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Many solutes with toxic capacity enter the body through the intestine. Changes in the composition of the intestinal microbiome, or changes in intestinal production, absorption, transfer, and metabolization may alter serum concentration of these toxins.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some uremic solutes interfere with functions that directly affect the biochemical action of other solutes (eg, the expression of parathyroid hormone [PTH] receptors, the response to 1,25(OH)2 vitamin D3, protein binding, breakdown, tubular transport, etc).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients with kidney failure use multiple medications. Interference of drugs with protein binding and/or tubular secretion of uremic solutes influences their biological effect.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lipophilic (protein-bound) compounds may be responsible at least in part for functional alterations in uremia; they are inadequately removed by current dialysis strategies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The main strategy that has been used to decrease uremic solute concentration is dialysis. However, dialysis is nonspecific and also removes essential compounds.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Uremic solutes accumulate not only in the plasma but also in the cells, where most of the biological activity is exerted. Removal of intracellular compounds during dialysis through the cell membrane may be hampered, resulting in multicompartmental kinetics and inadequate detoxification, unless dialysis length and/or frequency are increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of uremic retention solutes</strong> – Biochemical alterations are provoked by a broad spectrum of compounds:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some are small and water soluble (eg, urea, the guanidines, phosphate, oxalate, trimethylamine-N-oxide). (See <a class="local">'Small water-soluble compounds'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some are lipophilic and/or protein bound (eg, p-cresyl sulfate, 3-carboxy-4-metyl-5-propyl-2-furanpropionic acid [CMPF], homocysteine [Hcy], indoxyl sulfate, kynurenine). (See <a class="local">'Protein-bound compounds'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some are larger and in the middle-molecule range (eg, beta2-microglobulin [beta2-m], PTH, advanced glycosylation end products [AGEs], the cytokines, fibroblast growth factor-23). (See <a class="local">'Middle molecules'</a> above and <a class="local">'Large molecules'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some compounds from one group may impact generation and behavior of compounds from another group (eg, guanidines increasing generation of tumor necrosis factor-alpha [TNF-alpha]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Removal with extracorporeal therapies</strong> – Optimal removal for each type of molecule may be obtained with a different type of extracorporeal treatment (eg, by using large-pore membranes, convection, and/or dialyzers or devices with a high adsorptive capacity for some or several of the uremic toxins). Adsorption with the dialysis devices currently available is of little importance. More specific strategies using large adsorptive surface areas must be developed before adequate adsorption can be obtained. (See <a class="local">'General removal strategies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of intestinal uptake and residual kidney function</strong> – Solute concentration is also influenced by intestinal intake and preservation of kidney function:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intestinal uptake can be reduced by influencing dietary intake, by oral administration of sorbents, or by influencing the intestinal microbiome by administration of prebiotics, probiotics, or synbiotics.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preservation of residual kidney function is also an important manner to pursue additional removal of retention solutes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for better markers of uremia</strong> – A selection of appropriate marker molecules for uremic retention and dialytic removal should be reconsidered. It has become increasingly evident that the current markers, which are all small, water-soluble compounds (urea, creatinine), are not always representative in their kinetic behavior for middle molecules, lipophilic/protein-bound compounds, and even some other hydrosoluble compounds. On the other hand, it may be derisory to seek a marker that is representative for all solutes or even groups of solutes responsible for the uremic syndrome. Thus, a panel of solutes representative for a broad array of physicochemical characteristics with solid evidence of toxicity is desirable.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vanholder R, De Smet R, Hsu C, et al. Uremic toxicity: the middle molecule hypothesis revisited. Semin Nephrol 1994; 14:205.</a></li><li><a class="nounderline abstract_t">Vanholder R, Argilés A, Baurmeister U, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24:695.</a></li><li><a class="nounderline abstract_t">Vanholder R, Glorieux G, De Smet R, et al. New insights in uremic toxins. Kidney Int Suppl 2003; :S6.</a></li><li><a class="nounderline abstract_t">Yavuz A, Tetta C, Ersoy FF, et al. Uremic toxins: a new focus on an old subject. Semin Dial 2005; 18:203.</a></li><li><a class="nounderline abstract_t">Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357:1316.</a></li><li><a class="nounderline abstract_t">Vanholder R, Baurmeister U, Brunet P, et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19:863.</a></li><li><a class="nounderline abstract_t">Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23:1258.</a></li><li><a class="nounderline abstract_t">Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934.</a></li><li><a class="nounderline abstract_t">Rosner MH, Reis T, Husain-Syed F, et al. Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol 2021; 16:1918.</a></li><li><a class="nounderline abstract_t">Husain-Syed F, Vanholder R, Rosner MH, et al. Critical Appraisal of Limitations in the Current Definition/Classification of Uremic Toxins. Blood Purif 2023; 52:221.</a></li><li><a class="nounderline abstract_t">Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update. Toxins (Basel) 2018; 10.</a></li><li><a class="nounderline abstract_t">Vanholder R, De Smet R, Lameire NH. Redesigning the map of uremic toxins. Contrib Nephrol 2001; :42.</a></li><li><a class="nounderline abstract_t">Vanholder R, Gryp T, Glorieux G. Urea and chronic kidney disease: the comeback of the century? (in uraemia research). Nephrol Dial Transplant 2017.</a></li><li><a class="nounderline abstract_t">Lau WL, Vaziri ND. Urea, a true uremic toxin: the empire strikes back. Clin Sci (Lond) 2017; 131:3.</a></li><li><a class="nounderline abstract_t">Lim J, Gasson C, Kaji DM. Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest 1995; 96:2126.</a></li><li><a class="nounderline abstract_t">Prabhakar SS, Zeballos GA, Montoya-Zavala M, Leonard C. Urea inhibits inducible nitric oxide synthase in macrophage cell line. Am J Physiol 1997; 273:C1882.</a></li><li><a class="nounderline abstract_t">Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78:S102.</a></li><li><a class="nounderline abstract_t">Ok E, Basnakian AG, Apostolov EO, et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005; 68:173.</a></li><li><a class="nounderline abstract_t">Apostolov EO, Shah SV, Ok E, Basnakian AG. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007; 27:826.</a></li><li><a class="nounderline abstract_t">Sun JT, Yang K, Lu L, et al. Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function. Am J Physiol Renal Physiol 2016; 310:F511.</a></li><li><a class="nounderline abstract_t">D'Apolito M, Du X, Zong H, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest 2010; 120:203.</a></li><li><a class="nounderline abstract_t">Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013; 37:1.</a></li><li><a class="nounderline abstract_t">Trécherel E, Godin C, Louandre C, et al. Upregulation of BAD, a pro-apoptotic protein of the BCL2 family, in vascular smooth muscle cells exposed to uremic conditions. Biochem Biophys Res Commun 2012; 417:479.</a></li><li><a class="nounderline abstract_t">D'Apolito M, Du X, Pisanelli D, et al. Urea-induced ROS cause endothelial dysfunction in chronic renal failure. Atherosclerosis 2015; 239:393.</a></li><li><a class="nounderline abstract_t">Koppe L, Nyam E, Vivot K, et al. Urea impairs β cell glycolysis and insulin secretion in chronic kidney disease. J Clin Invest 2016; 126:3598.</a></li><li><a class="nounderline abstract_t">Lee JA, Lee HA, Sadler PJ. Uraemia: is urea more important than we think? Lancet 1991; 338:1438.</a></li><li><a class="nounderline abstract_t">Vanholder R, Glorieux G, Eloot S. Once upon a time in dialysis: the last days of Kt/V? Kidney Int 2015; 88:460.</a></li><li><a class="nounderline abstract_t">Johnson WJ, Hagge WW, Wagoner RD, et al. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972; 47:21.</a></li><li><a class="nounderline abstract_t">Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.</a></li><li><a class="nounderline abstract_t">Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307.</a></li><li><a class="nounderline abstract_t">Hirayama A, Noronha-Dutra AA, Gordge MP, et al. Inhibition of neutrophil superoxide production by uremic concentrations of guanidino compounds. J Am Soc Nephrol 2000; 11:684.</a></li><li><a class="nounderline abstract_t">Glorieux GL, Dhondt AW, Jacobs P, et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65:2184.</a></li><li><a class="nounderline abstract_t">Schepers E, Glorieux G, Dou L, et al. Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif 2010; 30:277.</a></li><li><a class="nounderline abstract_t">De Deyn PP, Macdonald RL. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol 1990; 28:627.</a></li><li><a class="nounderline abstract_t">Asaka M, Iida H, Izumino K, Sasayama S. Depressed natural killer cell activity in uremia. Evidence for immunosuppressive factor in uremic sera. Nephron 1988; 49:291.</a></li><li><a class="nounderline abstract_t">Perna AF, Ingrosso D, Satta E, et al. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004; 15:2747.</a></li><li><a class="nounderline abstract_t">Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44:445.</a></li><li><a class="nounderline abstract_t">MacAllister RJ, Rambausek MH, Vallance P, et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996; 11:2449.</a></li><li><a class="nounderline abstract_t">Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269:H1522.</a></li><li><a class="nounderline abstract_t">Anderstam B, Katzarski K, Bergström J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997; 8:1437.</a></li><li><a class="nounderline abstract_t">Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46:186.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109:172.</a></li><li><a class="nounderline abstract_t">Eiselt J, Rajdl D, Racek J, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study. Kidney Blood Press Res 2014; 39:50.</a></li><li><a class="nounderline abstract_t">Mihout F, Shweke N, Bigé N, et al. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis. J Pathol 2011; 223:37.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37:2024.</a></li><li><a class="nounderline abstract_t">von Leitner EC, Klinke A, Atzler D, et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 2011; 124:2735.</a></li><li><a class="nounderline abstract_t">Shafi T, Hostetter TH, Meyer TW, et al. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients. Am J Kidney Dis 2017; 70:48.</a></li><li><a class="nounderline abstract_t">Kielstein JT, Böger RH, Bode-Böger SM, et al. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004; 62:295.</a></li><li><a class="nounderline abstract_t">Bode-Böger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17:1128.</a></li><li><a class="nounderline abstract_t">Glorieux G, Schepers E, Schindler R, et al. A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test. Nephrol Dial Transplant 2009; 24:548.</a></li><li><a class="nounderline abstract_t">Schepers E, Barreto DV, Liabeuf S, et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2374.</a></li><li><a class="nounderline abstract_t">Speer T, Rohrer L, Blyszczuk P, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013; 38:754.</a></li><li><a class="nounderline abstract_t">Levillain O, Marescau B, de Deyn PP. Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy. Kidney Int 1995; 47:464.</a></li><li><a class="nounderline abstract_t">Eloot S, Torremans A, De Smet R, et al. Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. Kidney Int 2005; 67:1566.</a></li><li><a class="nounderline abstract_t">De Deyn PP, Robitaille P, Vanasse M, et al. Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations. Nephron 1995; 69:411.</a></li><li><a class="nounderline abstract_t">Eloot S, Torremans A, De Smet R, et al. Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis 2007; 50:279.</a></li><li><a class="nounderline abstract_t">Eloot S, van Biesen W, Dhondt A, et al. Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. Nephrol Dial Transplant 2009; 24:2225.</a></li><li><a class="nounderline abstract_t">Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112:1549.</a></li><li><a class="nounderline abstract_t">Koyama K, Ito A, Yamamoto J, et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis 2010; 55:1069.</a></li><li><a class="nounderline abstract_t">Marangella M, Petrarulo M, Cosseddu D, et al. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 1992; 19:546.</a></li><li><a class="nounderline abstract_t">Marangella M, Vitale C, Petrarulo M, et al. Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int 1995; 48:182.</a></li><li><a class="nounderline abstract_t">Salyer WR, Hutchins GM. Cardiac lesions in secondary oxalosis. Arch Intern Med 1974; 134:250.</a></li><li><a class="nounderline abstract_t">Recht PA, Tepedino GJ, Siecke NW, et al. Oxalic acid alters intracellular calcium in endothelial cells. Atherosclerosis 2004; 173:321.</a></li><li><a class="nounderline abstract_t">Levin RI, Kantoff PW, Jaffe EA. Uremic levels of oxalic acid suppress replication and migration of human endothelial cells. Arteriosclerosis 1990; 10:198.</a></li><li><a class="nounderline abstract_t">Mutsaers HA, Wilmer MJ, Reijnders D, et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta 2013; 1832:142.</a></li><li><a class="nounderline abstract_t">Wolfson M, Cohen AH, Kopple JD. Vitamin B-6 deficiency and renal function and structure in chronically uremic rats. Am J Clin Nutr 1991; 53:935.</a></li><li><a class="nounderline abstract_t">Morgan SH, Maher ER, Purkiss P, et al. Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine. Nephrol Dial Transplant 1988; 3:28.</a></li><li><a class="nounderline abstract_t">Marangella M, Bagnis C, Bruno M, et al. Determinants of oxalate balance in patients on chronic peritoneal dialysis. Am J Kidney Dis 1993; 21:419.</a></li><li><a class="nounderline abstract_t">Lindner A, Vanholder R, De Smet R, et al. HPLC fractions of human uremic plasma inhibit the RBC membrane calcium pump. Kidney Int 1997; 51:1042.</a></li><li><a class="nounderline abstract_t">Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57.</a></li><li><a class="nounderline abstract_t">Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575.</a></li><li><a class="nounderline abstract_t">Mueller DM, Allenspach M, Othman A, et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis 2015; 243:638.</a></li><li><a class="nounderline abstract_t">Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015; 116:448.</a></li><li><a class="nounderline abstract_t">Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-Oxide: The Good, the Bad and the Unknown. Toxins (Basel) 2016; 8.</a></li><li><a class="nounderline abstract_t">Ma J, Pazos IM, Gai F. Microscopic insights into the protein-stabilizing effect of trimethylamine N-oxide (TMAO). Proc Natl Acad Sci U S A 2014; 111:8476.</a></li><li><a class="nounderline abstract_t">Wang Z, Roberts AB, Buffa JA, et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell 2015; 163:1585.</a></li><li><a class="nounderline abstract_t">Coburn JW, Salusky IB. Control of serum phosphorus in uremia. N Engl J Med 1989; 320:1140.</a></li><li><a class="nounderline abstract_t">Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis 1995; 25:663.</a></li><li><a class="nounderline abstract_t">Imanishi Y, Koyama H, Inaba M, et al. Phosphorus intake regulates intestinal function and polyamine metabolism in uremia. Kidney Int 1996; 49:499.</a></li><li><a class="nounderline abstract_t">Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125:2243.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Rodriguez M, Ketteler M. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Semin Nephrol 2014; 34:151.</a></li><li><a class="nounderline abstract_t">Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584.</a></li><li><a class="nounderline abstract_t">Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393.</a></li><li><a class="nounderline abstract_t">Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 2016; 126:962.</a></li><li><a class="nounderline abstract_t">Loghman-Adham M. Role of phosphate retention in the progression of renal failure. J Lab Clin Med 1993; 122:16.</a></li><li><a class="nounderline abstract_t">Combe C, Aparicio M. Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 1994; 46:1381.</a></li><li><a class="nounderline abstract_t">Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607.</a></li><li><a class="nounderline abstract_t">Verbeke F, Van Biesen W, Honkanen E, et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011; 6:153.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.</a></li><li><a class="nounderline abstract_t">Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013; 83:959.</a></li><li><a class="nounderline abstract_t">Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382:1268.</a></li><li><a class="nounderline abstract_t">Lefebvre A, de Vernejoul MC, Gueris J, et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989; 36:1112.</a></li><li><a class="nounderline abstract_t">Boirie Y, Broyer M, Gagnadoux MF, et al. Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 2000; 58:236.</a></li><li><a class="nounderline abstract_t">Lesaffer G, De Smet R, Lameire N, et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15:50.</a></li><li><a class="nounderline abstract_t">Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16:3430.</a></li><li><a class="nounderline abstract_t">Sirich TL, Funk BA, Plummer NS, et al. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol 2014; 25:615.</a></li><li><a class="nounderline abstract_t">Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004; 44:278.</a></li><li><a class="nounderline abstract_t">Tijink MS, Wester M, Glorieux G, et al. Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma. Biomaterials 2013; 34:7819.</a></li><li><a class="nounderline abstract_t">de Loor H, Bammens B, Evenepoel P, et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51:1535.</a></li><li><a class="nounderline abstract_t">Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64:2238.</a></li><li><a class="nounderline abstract_t">De Smet R, Van Kaer J, Van Vlem B, et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003; 49:470.</a></li><li><a class="nounderline abstract_t">Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006; 70:794.</a></li><li><a class="nounderline abstract_t">Pham NM, Recht NS, Hostetter TH, Meyer TW. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008; 3:85.</a></li><li><a class="nounderline abstract_t">Vanholder R, Meert N, Van Biesen W, et al. Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes? Nat Clin Pract Nephrol 2009; 5:130.</a></li><li><a class="nounderline abstract_t">De Smet R, Glorieux G, Hsu C, Vanholder R. p-cresol and uric acid: two old uremic toxins revisited. Kidney Int Suppl 1997; 62:S8.</a></li><li><a class="nounderline abstract_t">Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996; 124:726.</a></li><li><a class="nounderline abstract_t">Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in uremia? Blood Purif 2010; 29:130.</a></li><li><a class="nounderline abstract_t">Bammens B, Evenepoel P, Keuleers H, et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69:1081.</a></li><li><a class="nounderline abstract_t">Meijers BK, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73:1174.</a></li><li><a class="nounderline abstract_t">Meijers BK, Claes K, Bammens B, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5:1182.</a></li><li><a class="nounderline abstract_t">Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25:1183.</a></li><li><a class="nounderline abstract_t">Wang CP, Lu LF, Yu TH, et al. Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 2010; 211:579.</a></li><li><a class="nounderline abstract_t">Massy ZA, Barreto DV, Barreto FC, Vanholder R. Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors. Atherosclerosis 2010; 211:381.</a></li><li><a class="nounderline abstract_t">Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26:938.</a></li><li><a class="nounderline abstract_t">Lin CJ, Wu V, Wu PC, Wu CJ. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. PLoS One 2015; 10:e0132589.</a></li><li><a class="nounderline abstract_t">Glorieux G, Vanholder R, Van Biesen W, et al. Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease. Nephrol Dial Transplant 2021; 36:998.</a></li><li><a class="nounderline abstract_t">Gryp T, Vanholder R, Vaneechoutte M, Glorieux G. p-Cresyl Sulfate. Toxins (Basel) 2017; 9.</a></li><li><a class="nounderline abstract_t">Schepers E, Meert N, Glorieux G, et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22:592.</a></li><li><a class="nounderline abstract_t">Meijers BK, Van Kerckhoven S, Verbeke K, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009; 54:891.</a></li><li><a class="nounderline abstract_t">Sun CY, Hsu HH, Wu MS. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant 2013; 28:70.</a></li><li><a class="nounderline abstract_t">Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One 2012; 7:e34026.</a></li><li><a class="nounderline abstract_t">Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 2012; 81:640.</a></li><li><a class="nounderline abstract_t">Watanabe H, Miyamoto Y, Honda D, et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 2013; 83:582.</a></li><li><a class="nounderline abstract_t">Koppe L, Pillon NJ, Vella RE, et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 2013; 24:88.</a></li><li><a class="nounderline abstract_t">Meert N, Schepers E, Glorieux G, et al. Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications. Nephrol Dial Transplant 2012; 27:2388.</a></li><li><a class="nounderline abstract_t">Pletinck A, Glorieux G, Schepers E, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol 2013; 24:1981.</a></li><li><a class="nounderline abstract_t">Sirich T, Meyer TW. Indoxyl sulfate: long suspected but not yet proven guilty. Clin J Am Soc Nephrol 2011; 6:3.</a></li><li><a class="nounderline abstract_t">Vanholder R, Schepers E, Pletinck A, et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 2014; 25:1897.</a></li><li><a class="nounderline abstract_t">Meert N, Beerenhout C, Schepers E, et al. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009; 22:352.</a></li><li><a class="nounderline abstract_t">Meert N, Waterloos MA, Van Landschoot M, et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs 2010; 34:580.</a></li><li><a class="nounderline abstract_t">Meert N, Eloot S, Schepers E, et al. Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrol Dial Transplant 2011; 26:2624.</a></li><li><a class="nounderline abstract_t">Sirich TL, Luo FJ, Plummer NS, et al. Selectively increasing the clearance of protein-bound uremic solutes. Nephrol Dial Transplant 2012; 27:1574.</a></li><li><a class="nounderline abstract_t">Basile C, Libutti P, Di Turo AL, et al. Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis. Nephrol Dial Transplant 2011; 26:1296.</a></li><li><a class="nounderline abstract_t">Eloot S, Schneditz D, Cornelis T, et al. Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis. PLoS One 2016; 11:e0147159.</a></li><li><a class="nounderline abstract_t">Meijers BK, Weber V, Bammens B, et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 2008; 32:214.</a></li><li><a class="nounderline abstract_t">Meijers BK, Verhamme P, Nevens F, et al. Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant 2007; 7:2195.</a></li><li><a class="nounderline abstract_t">Pavlenko D, van Geffen E, van Steenbergen MJ, et al. New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. Sci Rep 2016; 6:34429.</a></li><li><a class="nounderline abstract_t">Meert N, Eloot S, Waterloos MA, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009; 24:562.</a></li><li><a class="nounderline abstract_t">Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013; 83:308.</a></li><li><a class="nounderline abstract_t">Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003; 64:2196.</a></li><li><a class="nounderline abstract_t">Gryp T, De Paepe K, Vanholder R, et al. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. Kidney Int 2020; 97:1230.</a></li><li><a class="nounderline abstract_t">Niwa T, Ise M, Miyazaki T, Meada K. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993; 65:82.</a></li><li><a class="nounderline abstract_t">Kikuchi K, Itoh Y, Tateoka R, et al. Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1662.</a></li><li><a class="nounderline abstract_t">Phan O, Ivanovski O, Nguyen-Khoa T, et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112:2875.</a></li><li><a class="nounderline abstract_t">Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010; 25:2672.</a></li><li><a class="nounderline abstract_t">Riccio E, Sabbatini M, Bruzzese D, et al. Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial. Clin Exp Nephrol 2018; 22:529.</a></li><li><a class="nounderline abstract_t">Patel KP, Luo FJ, Plummer NS, et al. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin J Am Soc Nephrol 2012; 7:982.</a></li><li><a class="nounderline abstract_t">Aronov PA, Luo FJ, Plummer NS, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011; 22:1769.</a></li><li><a class="nounderline abstract_t">Vanholder R, Glorieux G. The intestine and the kidneys: a bad marriage can be hazardous. Clin Kidney J 2015; 8:168.</a></li><li><a class="nounderline abstract_t">Sirich TL, Plummer NS, Gardner CD, et al. Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin J Am Soc Nephrol 2014; 9:1603.</a></li><li><a class="nounderline abstract_t">Rossi M, Johnson DW, Morrison M, et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial. Clin J Am Soc Nephrol 2016; 11:223.</a></li><li><a class="nounderline abstract_t">Perna AF, Ingrosso D, De Santo NG, et al. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 1995; 47:247.</a></li><li><a class="nounderline abstract_t">Deguchi T, Ohtsuki S, Otagiri M, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney Int 2002; 61:1760.</a></li><li><a class="nounderline abstract_t">Vanholder R, Van Landschoot N, De Smet R, et al. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988; 33:996.</a></li><li><a class="nounderline abstract_t">Depner TA. Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 1981; 20:511.</a></li><li><a class="nounderline abstract_t">Lim CF, Bernard BF, de Jong M, et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993; 76:318.</a></li><li><a class="nounderline abstract_t">Motojima M, Nishijima F, Ikoma M, et al. Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40:461.</a></li><li><a class="nounderline abstract_t">Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124:96.</a></li><li><a class="nounderline abstract_t">Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 2002; 13:1711.</a></li><li><a class="nounderline abstract_t">Motojima M, Hosokawa A, Yamato H, et al. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63:1671.</a></li><li><a class="nounderline abstract_t">Lee CT, Kuo CC, Chen YM, et al. Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis. Perit Dial Int 2010; 30:456.</a></li><li><a class="nounderline abstract_t">Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007; 27:30.</a></li><li><a class="nounderline abstract_t">Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:1551.</a></li><li><a class="nounderline abstract_t">Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65:442.</a></li><li><a class="nounderline abstract_t">Dou L, Jourde-Chiche N, Faure V, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007; 5:1302.</a></li><li><a class="nounderline abstract_t">Itoh Y, Ezawa A, Kikuchi K, et al. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 2012; 403:1841.</a></li><li><a class="nounderline abstract_t">Faure V, Dou L, Sabatier F, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost 2006; 4:566.</a></li><li><a class="nounderline abstract_t">Ito S, Osaka M, Higuchi Y, et al. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. J Biol Chem 2010; 285:38869.</a></li><li><a class="nounderline abstract_t">Yamamoto H, Tsuruoka S, Ioka T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006; 69:1780.</a></li><li><a class="nounderline abstract_t">Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31:1771.</a></li><li><a class="nounderline abstract_t">Adijiang A, Goto S, Uramoto S, et al. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23:1892.</a></li><li><a class="nounderline abstract_t">Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, et al. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 2005; 20:1904.</a></li><li><a class="nounderline abstract_t">Iwasaki Y, Yamato H, Nii-Kono T, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006; 21:2768.</a></li><li><a class="nounderline abstract_t">Nii-Kono T, Iwasaki Y, Uchida M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007; 71:738.</a></li><li><a class="nounderline abstract_t">Gondouin B, Cerini C, Dou L, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 2013; 84:733.</a></li><li><a class="nounderline abstract_t">Chitalia VC, Shivanna S, Martorell J, et al. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation 2013; 127:365.</a></li><li><a class="nounderline abstract_t">Shivanna S, Kolandaivelu K, Shashar M, et al. The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol 2016; 27:189.</a></li><li><a class="nounderline abstract_t">Vlahu CA, Lemkes BA, Struijk DG, et al. Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol 2012; 23:1900.</a></li><li><a class="nounderline abstract_t">Asai H, Hirata J, Hirano A, et al. Activation of aryl hydrocarbon receptor mediates suppression of hypoxia-inducible factor-dependent erythropoietin expression by indoxyl sulfate. Am J Physiol Cell Physiol 2016; 310:C142.</a></li><li><a class="nounderline abstract_t">Barisione C, Garibaldi S, Furfaro AL, et al. Moderate Increase of Indoxyl Sulfate Promotes Monocyte Transition into Profibrotic Macrophages. PLoS One 2016; 11:e0149276.</a></li><li><a class="nounderline abstract_t">Hung SC, Kuo KL, Huang HL, et al. Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization. Kidney Int 2016; 89:574.</a></li><li><a class="nounderline abstract_t">Ochi A, Mori K, Nakatani S, et al. Indoxyl sulfate suppresses hepatic fetuin-A expression via the aryl hydrocarbon receptor in HepG2 cells. Nephrol Dial Transplant 2015; 30:1683.</a></li><li><a class="nounderline abstract_t">Ito S, Osaka M, Edamatsu T, et al. Crucial Role of the Aryl Hydrocarbon Receptor (AhR) in Indoxyl Sulfate-Induced Vascular Inflammation. J Atheroscler Thromb 2016; 23:960.</a></li><li><a class="nounderline abstract_t">Six I, Gross P, Rémond MC, et al. Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120. Atherosclerosis 2015; 243:248.</a></li><li><a class="nounderline abstract_t">Bobot M, Thomas L, Moyon A, et al. Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction. J Am Soc Nephrol 2020; 31:1509.</a></li><li><a class="nounderline abstract_t">Dou L, Sallée M, Cerini C, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol 2015; 26:876.</a></li><li><a class="nounderline abstract_t">Wu D, Nishimura N, Kuo V, et al. Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol 2011; 31:1260.</a></li><li><a class="nounderline abstract_t">Karbowska M, Kaminski TW, Marcinczyk N, et al. The Uremic Toxin Indoxyl Sulfate Accelerates Thrombotic Response after Vascular Injury in Animal Models. Toxins (Basel) 2017; 9.</a></li><li><a class="nounderline abstract_t">Satoh M, Hayashi H, Watanabe M, et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol 2003; 95:e111.</a></li><li><a class="nounderline abstract_t">Mor A, Pawlak K, Kalaska B, et al. Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. Int J Mol Sci 2020; 21.</a></li><li><a class="nounderline abstract_t">Barth MC, Ahluwalia N, Anderson TJ, et al. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 2009; 284:19189.</a></li><li><a class="nounderline abstract_t">Sallée M, Dou L, Cerini C, et al. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins (Basel) 2014; 6:934.</a></li><li><a class="nounderline abstract_t">Wang J, Simonavicius N, Wu X, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006; 281:22021.</a></li><li><a class="nounderline abstract_t">Alexander KS, Wu HQ, Schwarcz R, Bruno JP. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) 2012; 220:627.</a></li><li><a class="nounderline abstract_t">Sato T, Yamaguchi H, Kogawa T, et al. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver. J Pharm Pharm Sci 2014; 17:475.</a></li><li><a class="nounderline abstract_t">Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 2009; 204:309.</a></li><li><a class="nounderline abstract_t">Pawlak K, Mysliwiec M, Pawlak D. Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients. Thromb Haemost 2009; 102:49.</a></li><li><a class="nounderline abstract_t">Wu CC, Hsieh MY, Hung SC, et al. Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts. J Am Soc Nephrol 2016; 27:1254.</a></li><li><a class="nounderline abstract_t">Vanholder R, Nigam SK, Burtey S, Glorieux G. What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis. Toxins (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Vanholder RC, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992; 38:1429.</a></li><li><a class="nounderline abstract_t">De Smet R, Dhondt A, Eloot S, et al. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 2007; 22:2006.</a></li><li><a class="nounderline abstract_t">Schulman G, Agarwal R, Acharya M, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006; 47:565.</a></li><li><a class="nounderline abstract_t">Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009; 54:459.</a></li><li><a class="nounderline abstract_t">Ueda H, Shibahara N, Takagi S, et al. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007; 11:189.</a></li><li><a class="nounderline abstract_t">Ueda H, Shibahara N, Takagi S, et al. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30:856.</a></li><li><a class="nounderline abstract_t">Schulman G, Berl T, Beck GJ, et al. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol 2015; 26:1732.</a></li><li><a class="nounderline abstract_t">Cha RH, Kang SW, Park CW, et al. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction. Clin J Am Soc Nephrol 2016; 11:559.</a></li><li><a class="nounderline abstract_t">Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 2003; 41:S142.</a></li><li><a class="nounderline abstract_t">Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011; 26:1094.</a></li><li><a class="nounderline abstract_t">Joossens M, Faust K, Gryp T, et al. Gut microbiota dynamics and uraemic toxins: one size does not fit all. Gut 2019; 68:2257.</a></li><li><a class="nounderline abstract_t">Liabeuf S, Desjardins L, Massy ZA, et al. Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. Circ J 2016; 80:722.</a></li><li><a class="nounderline abstract_t">Veldeman L, Vanmassenhove J, Van Biesen W, et al. Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury. Int Urol Nephrol 2019; 51:293.</a></li><li><a class="nounderline abstract_t">Henderson SJ, Lindup WE. Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia. J Pharmacol Exp Ther 1992; 263:54.</a></li><li><a class="nounderline abstract_t">Costigan MG, Lindup WE. Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia. Kidney Int 1996; 49:634.</a></li><li><a class="nounderline abstract_t">Mabuchi H, Nakahashi H. Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 1988; 49:281.</a></li><li><a class="nounderline abstract_t">Niwa T, Aiuchi T, Nakaya K, et al. Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form. Clin Nephrol 1993; 39:92.</a></li><li><a class="nounderline abstract_t">Nagy E, Liu Y, Prentice KJ, et al. Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion. J Med Chem 2017; 60:1860.</a></li><li><a class="nounderline abstract_t">Prentice KJ, Luu L, Allister EM, et al. The furan fatty acid metabolite CMPF is elevated in diabetes and induces β cell dysfunction. Cell Metab 2014; 19:653.</a></li><li><a class="nounderline abstract_t">Prentice KJ, Wendell SG, Liu Y, et al. CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis. EBioMedicine 2018; 27:200.</a></li><li><a class="nounderline abstract_t">Mohan H, Brandt SL, Kim JH, et al. 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) prevents high fat diet-induced insulin resistance via maintenance of hepatic lipid homeostasis. Diabetes Obes Metab 2019; 21:61.</a></li><li><a class="nounderline abstract_t">Costigan MG, Callaghan CA, Lindup WE. Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4- methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure? Nephron 1996; 73:169.</a></li><li><a class="nounderline abstract_t">Niwa T, Yazawa T, Kodama T, et al. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990; 56:241.</a></li><li><a class="nounderline abstract_t">Jankowski J, van der Giet M, Jankowski V, et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003; 112:256.</a></li><li><a class="nounderline abstract_t">Yano S, Yamaguchi T, Kanazawa I, et al. The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. Nephrol Dial Transplant 2007; 22:3160.</a></li><li><a class="nounderline abstract_t">Schmidt S, Westhoff TH, Krauser P, et al. The uraemic toxin phenylacetic acid increases the formation of reactive oxygen species in vascular smooth muscle cells. Nephrol Dial Transplant 2008; 23:65.</a></li><li><a class="nounderline abstract_t">Cohen G, Raupachova J, Hörl WH. The uraemic toxin phenylacetic acid contributes to inflammation by priming polymorphonuclear leucocytes. Nephrol Dial Transplant 2013; 28:421.</a></li><li><a class="nounderline abstract_t">Mutsaers HA, van den Heuvel LP, Ringens LH, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One 2011; 6:e18438.</a></li><li><a class="nounderline abstract_t">Kurella Tamura M, Chertow GM, Depner TA, et al. Metabolic Profiling of Impaired Cognitive Function in Patients Receiving Dialysis. J Am Soc Nephrol 2016; 27:3780.</a></li><li><a class="nounderline abstract_t">Anderstam B, Mamoun AH, Södersten P, Bergström J. Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat. J Am Soc Nephrol 1996; 7:2453.</a></li><li><a class="nounderline abstract_t">Kamanna VS, Kashyap ML, Pai R, et al. Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol 1994; 5:193.</a></li><li><a class="nounderline abstract_t">Andress DL, Howard GA, Birnbaum RS. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int 1991; 39:942.</a></li><li><a class="nounderline abstract_t">Chmielewski M, Cohen G, Wiecek A, Jesús Carrero J. The peptidic middle molecules: is molecular weight doing the trick? Semin Nephrol 2014; 34:118.</a></li><li><a class="nounderline abstract_t">Blankestijn PJ, Vernooij RWM, Hockham C, et al. Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure. N Engl J Med 2023; 389:700.</a></li><li><a class="nounderline abstract_t">Weiner DE, Falzon L, Skoufos L, et al. Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial. Clin J Am Soc Nephrol 2020; 15:1310.</a></li><li><a class="nounderline abstract_t">Krishnasamy R, Hawley CM, Jardine MJ, et al. A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study. Blood Purif 2020; 49:468.</a></li><li><a class="nounderline abstract_t">Maduell F, Broseta JJ, Rodríguez-Espinosa D, et al. Comparison of four medium cut-off dialyzers. Clin Kidney J 2022; 15:2292.</a></li><li><a class="nounderline abstract_t">Jadoul M, Garbar C, Noël H, et al. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int 1997; 51:1928.</a></li><li><a class="nounderline abstract_t">Jadoul M, Garbar C, Vanholder R, et al. Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int 1998; 54:956.</a></li><li><a class="nounderline abstract_t">Wilson AM, Kimura E, Harada RK, et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007; 116:1396.</a></li><li><a class="nounderline abstract_t">Smith LK, He Y, Park JS, et al. β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat Med 2015; 21:932.</a></li><li><a class="nounderline abstract_t">Andoh T, Maki T, Li S, Uta D. β2-Microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1. Eur J Pharmacol 2017; 810:134.</a></li><li><a class="nounderline abstract_t">Kim M, Suzuki T, Kojima N, et al. Association Between Serum β2 -Microglobulin Levels and Prevalent and Incident Physical Frailty in Community-Dwelling Older Women. J Am Geriatr Soc 2017; 65:e83.</a></li><li><a class="nounderline abstract_t">Neirynck N, Glorieux G, Boelaert J, et al. Uremia-related oxidative stress in leukocytes is not triggered by β2-microglobulin. J Ren Nutr 2013; 23:456.</a></li><li><a class="nounderline abstract_t">Porter MY, Routledge KE, Radford SE, Hewitt EW. Characterization of the response of primary cells relevant to dialysis-related amyloidosis to β2-microglobulin monomer and fibrils. PLoS One 2011; 6:e27353.</a></li><li><a class="nounderline abstract_t">Pavone B, Bucci S, Sirolli V, et al. Beta2-microglobulin causes abnormal phosphatidylserine exposure in human red blood cells. Mol Biosyst 2011; 7:651.</a></li><li><a class="nounderline abstract_t">Menaa C, Esser E, Sprague SM. Beta2-microglobulin stimulates osteoclast formation. Kidney Int 2008; 73:1275.</a></li><li><a class="nounderline abstract_t">Josson S, Nomura T, Lin JT, et al. β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 2011; 71:2600.</a></li><li><a class="nounderline abstract_t">Giorgetti S, Raimondi S, Cassinelli S, et al. beta2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. Nephrol Dial Transplant 2009; 24:1176.</a></li><li><a class="nounderline abstract_t">Niwa T, Sato M, Katsuzaki T, et al. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996; 50:1303.</a></li><li><a class="nounderline abstract_t">Miyata T, Inagi R, Iida Y, et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93:521.</a></li><li><a class="nounderline abstract_t">Assounga A, Canaud B, Flavier JL, et al. [What does circulating beta 2 microglobulin signify in uremic patients on maintenance dialysis?]. Nephrologie 1987; 8:301.</a></li><li><a class="nounderline abstract_t">Mourad G, Argilés A. Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. J Am Soc Nephrol 1996; 7:798.</a></li><li><a class="nounderline abstract_t">Locatelli F, Mastrangelo F, Redaelli B, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50:1293.</a></li><li><a class="nounderline abstract_t">van Ypersele de Strihou C, Jadoul M, Malghem J, et al. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39:1012.</a></li><li><a class="nounderline abstract_t">Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17:546.</a></li><li><a class="nounderline abstract_t">Cheung AK, Greene T, Leypoldt JK, et al. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:69.</a></li><li><a class="nounderline abstract_t">Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 1994; 14:219.</a></li><li><a class="nounderline abstract_t">Ureña P, Kubrusly M, Mannstadt M, et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 1994; 45:605.</a></li><li><a class="nounderline abstract_t">Ureña P, Mannstadt M, Hruby M, et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int 1995; 47:1797.</a></li><li><a class="nounderline abstract_t">Stinghen AE, Massy ZA, Vlassara H, et al. Uremic Toxicity of Advanced Glycation End Products in CKD. J Am Soc Nephrol 2016; 27:354.</a></li><li><a class="nounderline abstract_t">Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318:1315.</a></li><li><a class="nounderline abstract_t">Papanastasiou P, Grass L, Rodela H, et al. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46:216.</a></li><li><a class="nounderline abstract_t">Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999; 55:389.</a></li><li><a class="nounderline abstract_t">Imani F, Horii Y, Suthanthiran M, et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993; 178:2165.</a></li><li><a class="nounderline abstract_t">Glorieux G, Helling R, Henle T, et al. In vitro evidence for immune activating effect of specific AGE structures retained in uremia. Kidney Int 2004; 66:1873.</a></li><li><a class="nounderline abstract_t">Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87:432.</a></li><li><a class="nounderline abstract_t">Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304.</a></li><li><a class="nounderline abstract_t">Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol 2004; 165:2033.</a></li><li><a class="nounderline abstract_t">Enomoto M, Adachi H, Yamagishi S, et al. Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism 2006; 55:912.</a></li><li><a class="nounderline abstract_t">Rubin MR, Paschalis EP, Poundarik A, et al. Advanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic Mice. PLoS One 2016; 11:e0154700.</a></li><li><a class="nounderline abstract_t">Zimmerman GA, Meistrell M 3rd, Bloom O, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 1995; 92:3744.</a></li><li><a class="nounderline abstract_t">Abel M, Ritthaler U, Zhang Y, et al. Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 1995; 10:1662.</a></li><li><a class="nounderline abstract_t">Henle T, Deppisch R, Beck W, et al. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999; 14:1968.</a></li><li><a class="nounderline abstract_t">Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62:301.</a></li><li><a class="nounderline abstract_t">Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343:1519.</a></li><li><a class="nounderline abstract_t">Galli F, Benedetti S, Floridi A, et al. Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005; 67:750.</a></li><li><a class="nounderline abstract_t">Fishbane S, Bucala R, Pereira BJ, et al. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 1997; 52:1645.</a></li><li><a class="nounderline abstract_t">Xue M, Weickert MO, Qureshi S, et al. Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. Diabetes 2016; 65:2282.</a></li><li><a class="nounderline abstract_t">Hörl WH, Haag-Weber M, Georgopoulos A, Block LH. Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci U S A 1990; 87:6353.</a></li><li><a class="nounderline abstract_t">Tschesche H, Kopp C, Hörl WH, Hempelmann U. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 1994; 269:30274.</a></li><li><a class="nounderline abstract_t">Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269:540.</a></li><li><a class="nounderline abstract_t">Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269:543.</a></li><li><a class="nounderline abstract_t">Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51:1980.</a></li><li><a class="nounderline abstract_t">Young GA, Woodrow G, Kendall S, et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant 1997; 12:2318.</a></li><li><a class="nounderline abstract_t">Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998; 9:1080.</a></li><li><a class="nounderline abstract_t">Heimbürger O, Lönnqvist F, Danielsson A, et al. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 1997; 8:1423.</a></li><li><a class="nounderline abstract_t">Jankowski J, Hagemann J, Yoon MS, et al. Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int 2001; 59:1134.</a></li><li><a class="nounderline abstract_t">Jankowski V, Karadogan S, Vanholder R, et al. Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. Kidney Int 2007; 71:994.</a></li><li><a class="nounderline abstract_t">Schepers E, Glorieux G, Jankowski V, et al. Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst. Nephrol Dial Transplant 2010; 25:2636.</a></li><li><a class="nounderline abstract_t">Jankowski V, Tölle M, Vanholder R, et al. Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 2005; 11:223.</a></li><li><a class="nounderline abstract_t">Kuczera P, Adamczak M, Wiecek A. Fibroblast Growth Factor-23-A Potential Uremic Toxin. Toxins (Basel) 2016; 8.</a></li><li><a class="nounderline abstract_t">Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010; 77:550.</a></li><li><a class="nounderline abstract_t">Neirynck N, Glorieux G, Schepers E, et al. Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders? Nephrol Dial Transplant 2015; 30:943.</a></li><li><a class="nounderline abstract_t">Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379:1214.</a></li><li><a class="nounderline abstract_t">Gajjala PR, Fliser D, Speer T, et al. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol Dial Transplant 2015; 30:1814.</a></li><li><a class="nounderline abstract_t">Cheung AK, Levin NW, Greene T, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003; 14:3251.</a></li><li><a class="nounderline abstract_t">Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20:645.</a></li><li><a class="nounderline abstract_t">Canaud B, Bragg-Gresham JL, Marshall MR, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006; 69:2087.</a></li><li><a class="nounderline abstract_t">Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol 2010; 21:1798.</a></li><li><a class="nounderline abstract_t">Grooteman MP, van den Dorpel MA, Bots ML, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23:1087.</a></li><li><a class="nounderline abstract_t">Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28:192.</a></li><li><a class="nounderline abstract_t">Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24:487.</a></li><li><a class="nounderline abstract_t">Peters SA, Bots ML, Canaud B, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant 2016; 31:978.</a></li><li><a class="nounderline abstract_t">Lornoy W, Becaus I, Billiouw JM, et al. Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. Am J Nephrol 1998; 18:105.</a></li><li><a class="nounderline abstract_t">Maduell F, del Pozo C, Garcia H, et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14:1202.</a></li><li><a class="nounderline abstract_t">Ward RA, Schmidt B, Hullin J, et al. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11:2344.</a></li><li><a class="nounderline abstract_t">Eloot S, Van Biesen W, Dhondt A, et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008; 73:765.</a></li><li><a class="nounderline abstract_t">Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005; 16:2421.</a></li><li><a class="nounderline abstract_t">Kirsch AH, Lyko R, Nilsson LG, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant 2017; 32:165.</a></li><li><a class="nounderline abstract_t">Devine E, Krieter DH, Rüth M, et al. Binding affinity and capacity for the uremic toxin indoxyl sulfate. Toxins (Basel) 2014; 6:416.</a></li><li><a class="nounderline abstract_t">Krieter DH, Devine E, Körner T, et al. Haemodiafiltration at increased plasma ionic strength for improved protein-bound toxin removal. Acta Physiol (Oxf) 2017; 219:510.</a></li><li><a class="nounderline abstract_t">Vanholder RC, Eloot S, Glorieux GL. Future Avenues to Decrease Uremic Toxin Concentration. Am J Kidney Dis 2016; 67:664.</a></li><li><a class="nounderline abstract_t">Ling WH, Hänninen O. Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. J Nutr 1992; 122:924.</a></li><li><a class="nounderline abstract_t">Birkett A, Muir J, Phillips J, et al. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996; 63:766.</a></li><li><a class="nounderline abstract_t">Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 2005; 15:77.</a></li><li><a class="nounderline abstract_t">Marquez IO, Tambra S, Luo FY, et al. Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 2011; 6:290.</a></li><li><a class="nounderline abstract_t">Eloot S, Van Biesen W, Glorieux G, et al. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? PLoS One 2013; 8:e76838.</a></li><li><a class="nounderline abstract_t">Masereeuw R, Mutsaers HA, Toyohara T, et al. The kidney and uremic toxin removal: glomerulus or tubule? Semin Nephrol 2014; 34:191.</a></li><li><a class="nounderline abstract_t">Buffington DA, Westover AJ, Johnston KA, Humes HD. The bioartificial kidney. Transl Res 2014; 163:342.</a></li><li><a class="nounderline abstract_t">Schepers E, Glorieux G, Dhondt A, et al. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009; 24:1429.</a></li><li><a class="nounderline abstract_t">Saigo C, Nomura Y, Yamamoto Y, et al. Meclofenamate elicits a nephropreventing effect in a rat model of ischemic acute kidney injury by suppressing indoxyl sulfate production and restoring renal organic anion transporters. Drug Des Devel Ther 2014; 8:1073.</a></li></ol></div><div id="topicVersionRevision">Topic 1916 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036355" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Uremic toxicity: the middle molecule hypothesis revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11817319" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Uremic toxicity: present state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694297" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : New insights in uremic toxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15934967" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Uremic toxins: a new focus on an old subject.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898101" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18287557" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A bench to bedside view of uremic toxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626821" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Normal and pathologic concentrations of uremic toxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12675874" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Review on uremic toxins: classification, concentration, and interindividual variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34233920" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Classification of Uremic Toxins and Their Role in Kidney Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36513030" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Critical Appraisal of Limitations in the Current Definition/Classification of Uremic Toxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29316724" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477754" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Redesigning the map of uremic toxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28407121" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Urea and chronic kidney disease: the comeback of the century? (in uraemia research).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27872172" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Urea, a true uremic toxin: the empire strikes back.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593597" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Urea inhibits NaK2Cl cotransport in human erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435493" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Urea inhibits inducible nitric oxide synthase in macrophage cell line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168993" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Carbamoylation of amino acids and proteins in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15954906" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255534" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26764205" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19955654" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23258127" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22172950" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Upregulation of BAD, a pro-apoptotic protein of the BCL2 family, in vascular smooth muscle cells exposed to uremic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25682038" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Urea-induced ROS cause endothelial dysfunction in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27525435" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Urea impairsβcell glycolysis and insulin secretion in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1683430" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Uraemia: is urea more important than we think?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061543" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Once upon a time in dialysis: the last days of Kt/V?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5008253" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of urea loading in patients with far-advanced renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12490682" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of dialysis dose and membrane flux in maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961019" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752527" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Inhibition of neutrophil superoxide production by uremic concentrations of guanidino compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149331" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079396" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2135950" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3261845" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Depressed natural killer cell activity in uremia. Evidence for immunosuppressive factor in uremic sera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466280" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8377388" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017621" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503244" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294836" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784625" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16112037" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662708" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24923294" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20845411" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809568" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : ADMA increases arterial stiffness and decreases cerebral blood flow in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22082678" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28089476" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15524060" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481412" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18768583" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the LAL-test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21817129" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23477738" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7536856" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780113" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7777105" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660029" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225018" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144995" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430500" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1595703" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7564076" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4843190" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cardiac lesions in secondary oxalosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064109" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Oxalic acid alters intracellular calcium in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317157" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Uremic levels of oxalic acid suppress replication and migration of human endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23017367" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2008872" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Vitamin B-6 deficiency and renal function and structure in chronically uremic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3132636" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Oxalate metabolism in end-stage renal disease: the effect of ascorbic acid and pyridoxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8465823" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Determinants of oxalate balance in patients on chronic peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083269" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : HPLC fractions of human uremic plasma inhibit the RBC membrane calcium pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475195" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23614584" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26554714" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25599331" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27834801" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Trimethylamine N-Oxide: The Good, the Bad and the Unknown.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24912147" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Microscopic insights into the protein-stabilizing effect of trimethylamine N-oxide (TMAO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26687352" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2710175" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Control of serum phosphorus in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7747720" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8821836" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Phosphorus intake regulates intestinal function and polyamine metabolism in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492635" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24780470" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687639" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21985788" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : FGF23 induces left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26878171" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : FGF23 signaling impairs neutrophil recruitment and host defense during CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320487" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Role of phosphate retention in the progression of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7853797" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Phosphorus and protein restriction and parathyroid function in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531176" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20829424" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644521" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254903" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23870817" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2557481" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Optimal correction of acidosis changes progression of dialysis osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10886568" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607767" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120820" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Removal of P-cresol sulfate by hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24231664" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15264186" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23876759" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040852" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633148" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12600960" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Toxicity of free p-cresol: a prospective and cross-sectional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820785" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18045861" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19107105" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350670" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : p-cresol and uric acid: two old uremic toxins revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633832" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093818" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The gut: the forgotten organ in uremia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421516" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305466" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Free p-cresol is associated with cardiovascular disease in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430946" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914995" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427046" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20471651" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20884620" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26173073" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33508125" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28146081" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : p-Cresyl Sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17040995" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19615803" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The uremic retention solute p-cresyl sulfate and markers of endothelial damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22610984" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22479508" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22237753" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325087" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23274953" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : p-Cresyl sulfate promotes insulin resistance associated with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167586" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: clinical data and pathophysiological implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24009240" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148244" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Indoxyl sulfate: long suspected but not yet proven guilty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24812165" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19557711" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Evolution of protein-bound uraemic solutes during predilution haemofiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20545662" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310741" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231033" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Selectively increasing the clearance of protein-bound uremic solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813765" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26799394" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Protein-Bound Uremic Toxin Profiling as a Tool to Optimize Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201285" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17640311" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Major coagulation disturbances during fractionated plasma separation and adsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27703258" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809977" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22992469" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Chronic kidney disease alters intestinal microbial flora.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633143" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Evidence for impaired assimilation of protein in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317112" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413797" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20036201" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267260" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172849" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29159529" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22490877" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784895" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Colonic contribution to uremic solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25815173" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The intestine and the kidneys: a bad marriage can be hazardous.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25147155" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26772193" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731153" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11967025" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3392889" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Drug protein binding in chronic renal failure: evaluation of nine drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6458729" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432774" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787646" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Role for "uremic toxin" in the progressive loss of intact nephrons in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035108" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089366" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12675842" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20338972" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215572" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696217" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717914" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403109" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447217" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16405517" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Elevation of circulating endothelial microparticles in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937831" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16612331" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047993" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334529" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985520" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16820376" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17264878" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636172" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23269489" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26019318" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23085635" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Damage of the endothelial glycocalyx in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26561638" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Activation of aryl hydrocarbon receptor mediates suppression of hypoxia-inducible factor-dependent erythropoietin expression by indoxyl sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26925780" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Moderate Increase of Indoxyl Sulfate Promotes Monocyte Transition into Profibrotic Macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26880454" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26068716" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Indoxyl sulfate suppresses hepatic fetuin-A expression via the aryl hydrocarbon receptor in HepG2 cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26860885" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Crucial Role of the Aryl Hydrocarbon Receptor (AhR) in Indoxyl Sulfate-Induced Vascular Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26408929" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Deleterious vascular effects of indoxyl sulfate and reversal by oral adsorbent AST-120.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32527975" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145928" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : The cardiovascular effect of the uremic solute indole-3 acetic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21441140" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28753957" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : The Uremic Toxin Indoxyl Sulfate Accelerates Thrombotic Response after Vascular Injury in Animal Models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14646363" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32825192" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473985" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599232" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754668" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22038535" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25579430" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823890" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19572067" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Hypercoagulability is independently associated with kynurenine pathway activation in dialysed uraemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453609" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Serum Indoxyl Sulfate Associates with Postangioplasty Thrombosis of Dialysis Grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35324718" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1643710" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Assessment of urea and other uremic markers for quantification of dialysis efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468506" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564934" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19615804" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498000" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18925523" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349205" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26912554" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612972" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20929916" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30464044" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Gut microbiota dynamics and uraemic toxins: one size does not fit all.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26841804" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30604232" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1403803" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Renal organic acid transport: uptake by rat kidney slices of a furan dicarboxylic acid which inhibits plasma protein binding of acidic ligands in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648903" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Plasma clearance in the rat of a furan dicarboxylic acid which accumulates in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3137482" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8448924" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Inhibition of mitochondrial respiration by furancarboxylic acid accumulated in uremic serum in its albumin-bound and non-dialyzable form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28171722" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703697" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : The furan fatty acid metabolite CMPF is elevated in diabetes and inducesβcell dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29290411" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30062833" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) prevents high fat diet-induced insulin resistance via maintenance of hepatic lipid homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8773339" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4- methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2077405" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12865413" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17640942" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17965436" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : The uraemic toxin phenylacetic acid increases the formation of reactive oxygen species in vascular smooth muscle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229930" id="rid226" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>227 : The uraemic toxin phenylacetic acid contributes to inflammation by priming polymorphonuclear leucocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21483698" id="rid227" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>228 : Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27444566" id="rid228" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>229 : Metabolic Profiling of Impaired Cognitive Function in Patients Receiving Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8959639" id="rid229" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>230 : Middle-sized molecule fractions isolated from uremic ultrafiltrate and normal urine inhibit ingestive behavior in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993998" id="rid230" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>231 : Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067211" id="rid231" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>232 : Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24780468" id="rid232" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>233 : The peptidic middle molecules: is molecular weight doing the trick?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37326323" id="rid233" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>234 : Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32843372" id="rid234" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>235 : Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31968346" id="rid235" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>236 : A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36381368" id="rid236" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>237 : Comparison of four medium cut-off dialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9186884" id="rid237" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>238 : Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9734623" id="rid238" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>239 : Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17724262" id="rid239" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>240 : Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26147761" id="rid240" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>241 : β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28687195" id="rid241" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>242 : β2-Microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28140452" id="rid242" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>243 : Association Between Serumβ2 -Microglobulin Levels and Prevalent and Incident Physical Frailty in Community-Dwelling Older Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24016624" id="rid243" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>244 : Uremia-related oxidative stress in leukocytes is not triggered byβ2-microglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22096558" id="rid244" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>245 : Characterization of the response of primary cells relevant to dialysis-related amyloidosis toβ2-microglobulin monomer and fibrils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21107472" id="rid245" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>246 : Beta2-microglobulin causes abnormal phosphatidylserine exposure in human red blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18368032" id="rid246" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>247 : Beta2-microglobulin stimulates osteoclast formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427356" id="rid247" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>248 : β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19008236" id="rid248" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>249 : beta2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8887292" id="rid249" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>250 : Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113390" id="rid250" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>251 : Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3330579" id="rid251" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>252 : [What does circulating beta 2 microglobulin signify in uremic patients on maintenance dialysis?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8738817" id="rid252" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>253 : Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8887291" id="rid253" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>254 : Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067196" id="rid254" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>255 : Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16382021" id="rid255" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>256 : Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057309" id="rid256" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>257 : Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036356" id="rid257" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>258 : Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164450" id="rid258" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>259 : The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7643551" id="rid259" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>260 : Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26311460" id="rid260" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>261 : Uremic Toxicity of Advanced Glycation End Products in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3283558" id="rid261" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>262 : Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933840" id="rid262" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>263 : Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9987064" id="rid263" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>264 : Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245789" id="rid264" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>265 : Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496158" id="rid265" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>266 : In vitro evidence for immune activating effect of specific AGE structures retained in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991829" id="rid266" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>267 : Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8731095" id="rid267" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>268 : Advanced oxidation protein products as a novel marker of oxidative stress in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579446" id="rid268" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>269 : Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16784963" id="rid269" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>270 : Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27140650" id="rid270" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>271 : Advanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731977" id="rid271" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>272 : Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559486" id="rid272" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>273 : Expression of receptors for advanced glycosylated end-products in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10462279" id="rid273" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>274 : Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081592" id="rid274" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>275 : Advanced glycation end products and mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7911868" id="rid275" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>276 : Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673326" id="rid276" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>277 : Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9407512" id="rid277" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>278 : Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27207552" id="rid278" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>279 : Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385596" id="rid279" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>280 : Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7982938" id="rid280" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>281 : Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624776" id="rid281" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>282 : Effects of the obese gene product on body weight regulation in ob/ob mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624777" id="rid282" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>283 : Weight-reducing effects of the plasma protein encoded by the obese gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9186891" id="rid283" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>284 : Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9394318" id="rid284" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>285 : Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9621292" id="rid285" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>286 : Leptin, body composition, and indices of malnutrition in patients on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294834" id="rid286" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>287 : Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231371" id="rid287" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>288 : Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17361116" id="rid288" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>289 : Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190246" id="rid289" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>290 : Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15665829" id="rid290" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>291 : Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941640" id="rid291" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>292 : Fibroblast Growth Factor-23-A Potential Uremic Toxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20016471" id="rid292" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>293 : Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25609738" id="rid293" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>294 : Pro-inflammatory cytokines and leukocyte oxidative burst in chronic kidney disease: culprits or innocent bystanders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421340" id="rid294" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>295 : The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862763" id="rid295" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>296 : Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638924" id="rid296" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>297 : Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092122" id="rid297" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>298 : Effect of membrane permeability on survival of hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16641921" id="rid298" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>299 : Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813866" id="rid299" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>300 : Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22539829" id="rid300" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>301 : Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229932" id="rid301" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>302 : Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23411788" id="rid302" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>303 : High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492924" id="rid303" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>304 : Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9569951" id="rid304" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>305 : Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344362" id="rid305" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>306 : Change from conventional haemodiafiltration to on-line haemodiafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095657" id="rid306" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>307 : A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160958" id="rid307" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>308 : Impact of hemodialysis duration on the removal of uremic retention solutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15975998" id="rid308" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>309 : Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27587605" id="rid309" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>310 : Performance of hemodialysis with novel medium cut-off dialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24469432" id="rid310" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>311 : Binding affinity and capacity for the uremic toxin indoxyl sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27259463" id="rid311" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>312 : Haemodiafiltration at increased plasma ionic strength for improved protein-bound toxin removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26500179" id="rid312" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>313 : Future Avenues to Decrease Uremic Toxin Concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552366" id="rid313" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>314 : Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8615362" id="rid314" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>315 : Resistant starch lowers fecal concentrations of ammonia and phenols in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15648012" id="rid315" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>316 : Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030575" id="rid316" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>317 : Contribution of residual function to removal of protein-bound solutes in hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24236005" id="rid317" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>318 : Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24780473" id="rid318" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>319 : The kidney and uremic toxin removal: glomerulus or tubule?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24269374" id="rid319" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>320 : The bioartificial kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059932" id="rid320" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>321 : Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25143712" id="rid321" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>322 : Meclofenamate elicits a nephropreventing effect in a rat model of ischemic acute kidney injury by suppressing indoxyl sulfate production and restoring renal organic anion transporters.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
